NZ623518B2 - Modulation of structured polypeptide specificity - Google Patents
Modulation of structured polypeptide specificity Download PDFInfo
- Publication number
- NZ623518B2 NZ623518B2 NZ623518A NZ62351812A NZ623518B2 NZ 623518 B2 NZ623518 B2 NZ 623518B2 NZ 623518 A NZ623518 A NZ 623518A NZ 62351812 A NZ62351812 A NZ 62351812A NZ 623518 B2 NZ623518 B2 NZ 623518B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- peptide
- peptide ligand
- loop
- polypeptide
- ligand according
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 161
- 230000000051 modifying Effects 0.000 title description 6
- 230000027455 binding Effects 0.000 claims abstract description 235
- 239000003446 ligand Substances 0.000 claims abstract description 127
- 150000001413 amino acids Chemical class 0.000 claims abstract description 111
- 102000001399 Kallikreins Human genes 0.000 claims abstract description 66
- 108060005987 Kallikreins Proteins 0.000 claims abstract description 66
- 239000002062 molecular scaffold Substances 0.000 claims abstract description 63
- 241000282414 Homo sapiens Species 0.000 claims abstract description 61
- 235000001014 amino acid Nutrition 0.000 claims description 123
- 108091005771 Peptidases Proteins 0.000 claims description 31
- 239000004365 Protease Substances 0.000 claims description 31
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 claims description 22
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N-monomethyl-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 claims description 19
- 235000018417 cysteine Nutrition 0.000 claims description 19
- 102000033147 ERVK-25 Human genes 0.000 claims description 15
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 12
- 241000282619 Hylobates lar Species 0.000 claims description 10
- KVVMXWRFYAGASO-UHFFFAOYSA-N azetidine-1-carboxylic acid Chemical compound OC(=O)N1CCC1 KVVMXWRFYAGASO-UHFFFAOYSA-N 0.000 claims description 10
- 229920000453 Consensus sequence Polymers 0.000 claims description 6
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 6
- 230000015556 catabolic process Effects 0.000 claims description 5
- 230000004059 degradation Effects 0.000 claims description 5
- 238000006731 degradation reaction Methods 0.000 claims description 5
- 229960002591 Hydroxyproline Drugs 0.000 claims description 3
- 238000007112 amidation reaction Methods 0.000 claims description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N trans-L-hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 3
- 238000006640 acetylation reaction Methods 0.000 claims description 2
- KISFEBPWFCGRGN-UHFFFAOYSA-M sodium;2-(2,4-dichlorophenoxy)ethyl sulfate Chemical compound [Na+].[O-]S(=O)(=O)OCCOC1=CC=C(Cl)C=C1Cl KISFEBPWFCGRGN-UHFFFAOYSA-M 0.000 claims 1
- 229940024606 Amino Acids Drugs 0.000 description 78
- 229940019746 Antifibrinolytic amino acids Drugs 0.000 description 78
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 78
- 102000004196 processed proteins & peptides Human genes 0.000 description 72
- 108090000765 processed proteins & peptides Proteins 0.000 description 72
- 241000700159 Rattus Species 0.000 description 55
- 210000002381 Plasma Anatomy 0.000 description 48
- 230000000694 effects Effects 0.000 description 41
- 102000003827 Plasma kallikrein Human genes 0.000 description 38
- 108090000113 Plasma kallikrein Proteins 0.000 description 38
- 238000006467 substitution reaction Methods 0.000 description 34
- 238000004166 bioassay Methods 0.000 description 33
- 230000036515 potency Effects 0.000 description 32
- 210000004027 cells Anatomy 0.000 description 31
- 239000000203 mixture Substances 0.000 description 27
- 238000000034 method Methods 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 21
- 230000036908 Plasma Stability Effects 0.000 description 20
- 102000004965 antibodies Human genes 0.000 description 19
- 108090001123 antibodies Proteins 0.000 description 19
- 230000002401 inhibitory effect Effects 0.000 description 19
- 150000007523 nucleic acids Chemical class 0.000 description 19
- 125000003275 alpha amino acid group Chemical group 0.000 description 18
- 125000002619 bicyclic group Chemical group 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 239000002253 acid Substances 0.000 description 17
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 16
- 102000035443 Peptidases Human genes 0.000 description 16
- 230000004048 modification Effects 0.000 description 16
- 238000006011 modification reaction Methods 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 235000009697 arginine Nutrition 0.000 description 11
- 229940079593 drugs Drugs 0.000 description 11
- 230000001965 increased Effects 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000000159 protein binding assay Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000004475 Arginine Substances 0.000 description 10
- 230000036499 Half live Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 238000007069 methylation reaction Methods 0.000 description 10
- 230000002194 synthesizing Effects 0.000 description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 230000002708 enhancing Effects 0.000 description 9
- 125000000524 functional group Chemical group 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000002823 phage display Methods 0.000 description 9
- 230000002797 proteolythic Effects 0.000 description 9
- 230000002829 reduced Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 150000003384 small molecules Chemical class 0.000 description 9
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 8
- 229940088598 Enzyme Drugs 0.000 description 8
- 150000001350 alkyl halides Chemical class 0.000 description 8
- -1 benzylic halogen Chemical class 0.000 description 8
- 230000002209 hydrophobic Effects 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 101710009757 UROD Proteins 0.000 description 7
- 235000004279 alanine Nutrition 0.000 description 7
- 125000000511 arginine group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 235000018977 lysine Nutrition 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 125000001116 prolino group Chemical class [H]OC(=O)C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 7
- GHITVUOBZBZMND-UHFFFAOYSA-N 1,3,5-tris(bromomethyl)benzene Chemical compound BrCC1=CC(CBr)=CC(CBr)=C1 GHITVUOBZBZMND-UHFFFAOYSA-N 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 230000001808 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 125000005647 linker group Chemical group 0.000 description 6
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 6
- 238000002703 mutagenesis Methods 0.000 description 6
- 231100000350 mutagenesis Toxicity 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000001225 therapeutic Effects 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 5
- 239000002609 media Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 230000000717 retained Effects 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 4
- 101710027066 ALB Proteins 0.000 description 4
- 101710038084 ARG1 Proteins 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 108010069514 Cyclic Peptides Proteins 0.000 description 4
- 102000001189 Cyclic Peptides Human genes 0.000 description 4
- 150000008574 D-amino acids Chemical class 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N Succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
- 101710017525 TINAGL1 Proteins 0.000 description 4
- 239000004473 Threonine Chemical group 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000003115 biocidal Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 125000003636 chemical group Chemical group 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000003834 intracellular Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000003389 potentiating Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 108010037022 subtiligase Proteins 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 description 3
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 3
- 108010003596 Antennapedia Homeodomain Protein Proteins 0.000 description 3
- PXXJHWLDUBFPOL-UHFFFAOYSA-N Benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N Benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 108010080805 Factor XIa Proteins 0.000 description 3
- IRXSLJNXXZKURP-UHFFFAOYSA-N Fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 229920002521 Macromolecule Polymers 0.000 description 3
- 206010028417 Myasthenia gravis Diseases 0.000 description 3
- 229920001850 Nucleic acid sequence Polymers 0.000 description 3
- 229920000272 Oligonucleotide Polymers 0.000 description 3
- 230000037289 Plasma half life Effects 0.000 description 3
- 230000037240 Plasma half-life Effects 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 108010077895 Sarcosine Proteins 0.000 description 3
- 102000012479 Serine Proteases Human genes 0.000 description 3
- 108010022999 Serine Proteases Proteins 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 229940035295 Ting Drugs 0.000 description 3
- ZHHGTMQHUWDEJF-UHFFFAOYSA-N [(6-chlorobenzotriazol-1-yl)oxy-(dimethylamino)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.C1=C(Cl)C=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 ZHHGTMQHUWDEJF-UHFFFAOYSA-N 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 150000001345 alkine derivatives Chemical class 0.000 description 3
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007172 antigens Proteins 0.000 description 3
- 102000038129 antigens Human genes 0.000 description 3
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 230000003197 catalytic Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 230000001627 detrimental Effects 0.000 description 3
- 230000002349 favourable Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000002068 genetic Effects 0.000 description 3
- 125000001165 hydrophobic group Chemical group 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 238000002824 mRNA display Methods 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 238000009740 moulding (composite fabrication) Methods 0.000 description 3
- 108010087904 neutravidin Proteins 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 239000000816 peptidomimetic Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001681 protective Effects 0.000 description 3
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine zwitterion Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- FUOOLUPWFVMBKG-UHFFFAOYSA-N α-aminoisobutanoic acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- PSFABYLDRXJYID-VKHMYHEASA-N (2S)-3-hydroxy-2-(methylazaniumyl)propanoate Chemical compound CN[C@@H](CO)C(O)=O PSFABYLDRXJYID-VKHMYHEASA-N 0.000 description 2
- BHIFXIATEXVOQA-UHFFFAOYSA-N 1,3,5-tris(bromomethyl)-2,4,6-trimethylbenzene Chemical group CC1=C(CBr)C(C)=C(CBr)C(C)=C1CBr BHIFXIATEXVOQA-UHFFFAOYSA-N 0.000 description 2
- ZHKQIADIIYMFOZ-UHFFFAOYSA-N 2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]acetic acid Chemical compound C1=CC=C2C(COC(=O)N(CC(O)=O)C)C3=CC=CC=C3C2=C1 ZHKQIADIIYMFOZ-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- PRKQVKDSMLBJBJ-UHFFFAOYSA-N Ammonium carbonate Chemical compound N.N.OC(O)=O PRKQVKDSMLBJBJ-UHFFFAOYSA-N 0.000 description 2
- 206010003246 Arthritis Diseases 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 2
- 102000019679 Cell-Penetrating Peptides Human genes 0.000 description 2
- 229960005091 Chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N Chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-K Disodium phosphate Chemical compound [Na+].[Na+].[O-]P([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-K 0.000 description 2
- 229960004679 Doxorubicin Drugs 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010048653 Enzyme inhibition Diseases 0.000 description 2
- 229960005420 Etoposide Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 230000035693 Fab Effects 0.000 description 2
- 108010071241 Factor XIIa Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000005319 Human Immunodeficiency Virus tat Gene Products Human genes 0.000 description 2
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- JTEDVYBZBROSJT-UHFFFAOYSA-N Indole-3-butyric acid Natural products C1=CC=C2C(CCCC(=O)O)=CNC2=C1 JTEDVYBZBROSJT-UHFFFAOYSA-N 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241001182492 Nes Species 0.000 description 2
- 241000750002 Nestor Species 0.000 description 2
- 229960001592 Paclitaxel Drugs 0.000 description 2
- 229940012957 Plasmin Drugs 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZKZBPNGNEQAJSX-REOHCLBHSA-N Selenocysteine Chemical compound [SeH]C[C@H](N)C(O)=O ZKZBPNGNEQAJSX-REOHCLBHSA-N 0.000 description 2
- 229940055619 Selenocysteine Drugs 0.000 description 2
- FDKWRPBBCBCIGA-UWTATZPHSA-N Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 2
- 108060008443 TPPP Proteins 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N VANCOMYCIN Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- 229960003165 Vancomycin Drugs 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 238000009632 agar plate Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229930013930 alkaloids Natural products 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
- 125000003286 aryl halide group Chemical group 0.000 description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 238000002819 bacterial display Methods 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 102000024070 binding proteins Human genes 0.000 description 2
- 108091007650 binding proteins Proteins 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000005997 bromomethyl group Chemical group 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000002596 correlated Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical group NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 150000002678 macrocyclic compounds Chemical class 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 210000004962 mammalian cells Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 230000003278 mimic Effects 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000000896 plasminic Effects 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 230000000750 progressive Effects 0.000 description 2
- 230000002633 protecting Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000002818 protein evolution Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002702 ribosome display Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 235000016491 selenocysteine Nutrition 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229930003347 taxol Natural products 0.000 description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229960005486 vaccines Drugs 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 1
- ZPGDWQNBZYOZTI-GOSISDBHSA-N (2R)-1-(9H-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-GOSISDBHSA-N 0.000 description 1
- SIRPVCUJLVXZPW-LJQANCHMSA-N (2R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-(1H-imidazol-5-yl)propanoic acid Chemical compound C([C@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CNC=N1 SIRPVCUJLVXZPW-LJQANCHMSA-N 0.000 description 1
- MGHMWKZOLAAOTD-XMMPIXPASA-N (2R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-(1H-indol-3-yl)propanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@@H](C(=O)O)CC1=CNC2=CC=CC=C12 MGHMWKZOLAAOTD-XMMPIXPASA-N 0.000 description 1
- XSGMGAINOILNJR-PGUFJCEWSA-N (2R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-methyl-3-tritylsulfanylbutanoic acid Chemical compound CC(C)([C@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(O)=O)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XSGMGAINOILNJR-PGUFJCEWSA-N 0.000 description 1
- CBPJQFCAFFNICX-LJQANCHMSA-N (2R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-LJQANCHMSA-N 0.000 description 1
- WDGICUODAOGOMO-PGUFJCEWSA-N (2R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-PGUFJCEWSA-N 0.000 description 1
- QWXZOFZKSQXPDC-LLVKDONJSA-N (2R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-LLVKDONJSA-N 0.000 description 1
- HNICLNKVURBTKV-MUUNZHRXSA-N (2R)-5-[[amino-[(2,2,4,6,7-pentamethyl-3H-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9H-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-MUUNZHRXSA-N 0.000 description 1
- CKLAZLINARHOTG-IBGZPJMESA-N (2S)-1-(9H-fluoren-9-ylmethoxycarbonyl)piperidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 CKLAZLINARHOTG-IBGZPJMESA-N 0.000 description 1
- PENQOTJCVODUQU-NDEPHWFRSA-N (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3,3-diphenylpropanoic acid Chemical compound C=1C=CC=CC=1C([C@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(=O)O)C1=CC=CC=C1 PENQOTJCVODUQU-NDEPHWFRSA-N 0.000 description 1
- VSGACONKQRJFGX-NDEPHWFRSA-N (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-(4-phenylphenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(C=C1)=CC=C1C1=CC=CC=C1 VSGACONKQRJFGX-NDEPHWFRSA-N 0.000 description 1
- VVQIIIAZJXTLRE-QMMMGPOBSA-N (2S)-2-amino-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC(C)(C)OC(=O)NCCCC[C@H](N)C(O)=O VVQIIIAZJXTLRE-QMMMGPOBSA-N 0.000 description 1
- NBMSMZSRTIOFOK-SFHVURJKSA-N (2S)-5-(carbamoylamino)-2-(9H-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCNC(=O)N)C(O)=O)C3=CC=CC=C3C2=C1 NBMSMZSRTIOFOK-SFHVURJKSA-N 0.000 description 1
- LIRBCUNCXDZOOU-HSZRJFAPSA-N (3R)-2-(9H-fluoren-9-ylmethoxycarbonyl)-3,4-dihydro-1H-isoquinoline-3-carboxylic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N1CC2=CC=CC=C2C[C@@H]1C(=O)O LIRBCUNCXDZOOU-HSZRJFAPSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- MKDZJIHLRSIZOV-UHFFFAOYSA-N 1,2,3-tribromo-4-phenylbenzene Chemical compound BrC1=C(Br)C(Br)=CC=C1C1=CC=CC=C1 MKDZJIHLRSIZOV-UHFFFAOYSA-N 0.000 description 1
- UMKPSDHZXLYFJF-UHFFFAOYSA-N 1,3,5-tris(bromomethyl)-2,4,6-triethylbenzene Chemical compound CCC1=C(CBr)C(CC)=C(CBr)C(CC)=C1CBr UMKPSDHZXLYFJF-UHFFFAOYSA-N 0.000 description 1
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 1
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-Aminocyclopropane-1-carboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 description 1
- PWTGPQMQEULXFR-UHFFFAOYSA-N 1-[2,3-bis(2,5-dioxopyrrol-1-yl)phenyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C1=CC=CC(N2C(C=CC2=O)=O)=C1N1C(=O)C=CC1=O PWTGPQMQEULXFR-UHFFFAOYSA-N 0.000 description 1
- UCKPWPPRJHUUPL-UHFFFAOYSA-N 1-[2-[2,3-bis[2-(2,5-dioxopyrrol-1-yl)ethyl]phenyl]ethyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1CCC1=CC=CC(CCN2C(C=CC2=O)=O)=C1CCN1C(=O)C=CC1=O UCKPWPPRJHUUPL-UHFFFAOYSA-N 0.000 description 1
- WHEOHCIKAJUSJC-UHFFFAOYSA-N 1-[2-[bis[2-(2,5-dioxopyrrol-1-yl)ethyl]amino]ethyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1CCN(CCN1C(C=CC1=O)=O)CCN1C(=O)C=CC1=O WHEOHCIKAJUSJC-UHFFFAOYSA-N 0.000 description 1
- HOZZVEPRYYCBTO-UHFFFAOYSA-N 2-(9H-fluoren-9-ylmethoxycarbonylamino)-2-methylpropanoic acid Chemical compound C1=CC=C2C(COC(=O)NC(C)(C)C(O)=O)C3=CC=CC=C3C2=C1 HOZZVEPRYYCBTO-UHFFFAOYSA-N 0.000 description 1
- FIHDROCXVRQYAL-UHFFFAOYSA-N 2-(9H-fluoren-9-ylmethoxycarbonylamino)-2-propylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)NC(CCC)(CCC)C(O)=O)C3=CC=CC=C3C2=C1 FIHDROCXVRQYAL-UHFFFAOYSA-N 0.000 description 1
- AJEIBHNKBLRDNT-UHFFFAOYSA-N 2-[3,5-bis(carboxymethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC(CC(O)=O)=CC(CC(O)=O)=C1 AJEIBHNKBLRDNT-UHFFFAOYSA-N 0.000 description 1
- MOKSHZWZRKXXAO-UHFFFAOYSA-N 2-[4-(aminomethyl)phenyl]guanidine Chemical class NCC1=CC=C(NC(N)=N)C=C1 MOKSHZWZRKXXAO-UHFFFAOYSA-N 0.000 description 1
- CDUQMGQIHYISOP-UHFFFAOYSA-N 2-cyano-3-phenylprop-2-enoic acid Chemical compound OC(=O)C(C#N)=CC1=CC=CC=C1 CDUQMGQIHYISOP-UHFFFAOYSA-N 0.000 description 1
- QRJZGVVKGFIGLI-UHFFFAOYSA-N 2-phenylguanidine Chemical class NC(=N)NC1=CC=CC=C1 QRJZGVVKGFIGLI-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- LINBWYYLPWJQHE-UHFFFAOYSA-N 3-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCC(=O)O)C3=CC=CC=C3C2=C1 LINBWYYLPWJQHE-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 1
- 229940009456 Adriamycin Drugs 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960001220 Amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N Amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 229920002395 Aptamer Polymers 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- 229960002170 Azathioprine Drugs 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 102000024969 Bacterial Proteins Human genes 0.000 description 1
- 206010060945 Bacterial infection Diseases 0.000 description 1
- 229960001561 Bleomycin Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 229940121384 CXC chemokine receptor type 4 (CXCR4) antagonists Drugs 0.000 description 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 108090000617 Cathepsin G Proteins 0.000 description 1
- 102000004173 Cathepsin G Human genes 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N Cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 229940119017 Cyclosporine Drugs 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- 150000008541 D-alanines Chemical class 0.000 description 1
- 125000000052 D-arginine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])N([H])C(N([H])[H])=N[H] 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- XUJNEKJLAYXESH-UWTATZPHSA-N D-cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 description 1
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 1
- 125000000237 D-prolino group Chemical group [H]OC(=O)[C@]1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- UMFJAHHVKNCGLG-UHFFFAOYSA-N DMNA Chemical compound CN(C)N=O UMFJAHHVKNCGLG-UHFFFAOYSA-N 0.000 description 1
- 108009000097 DNA Replication Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101700011961 DPOM Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 229960000640 Dactinomycin Drugs 0.000 description 1
- 208000004275 Demyelinating Disease Diseases 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N Depacane Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 229960001904 EPIRUBICIN Drugs 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 210000002683 Foot Anatomy 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N Guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- YPJUNDFVDDCYIH-UHFFFAOYSA-N Heptafluorobutyric acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)F YPJUNDFVDDCYIH-UHFFFAOYSA-N 0.000 description 1
- 206010019860 Hereditary angioedema Diseases 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 Ifosfamide Drugs 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 108010060231 Insect Proteins Proteins 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N Iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 210000000554 Iris Anatomy 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 101800000268 Leader protease Proteins 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 206010025135 Lupus erythematosus Diseases 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 101710029649 MDV043 Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 102000001777 Matrix Metalloproteinase 8 Human genes 0.000 description 1
- 108010015318 Matrix Metalloproteinase 8 Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- 102000001796 Melanocortin 4 receptor Human genes 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- 108060004843 Mical Proteins 0.000 description 1
- 102000015528 Myelin Basic Protein Human genes 0.000 description 1
- 108010025255 Myelin Basic Protein Proteins 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 101700021572 NCOA6 Proteins 0.000 description 1
- XRARAKHBJHWUHW-UHFFFAOYSA-N Neoline Chemical compound OC1C2C3C4(C5C6OC)C(O)CCC5(COC)CN(CC)C4C6C2(O)CC(OC)C1C3 XRARAKHBJHWUHW-UHFFFAOYSA-N 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229940099990 Ogen Drugs 0.000 description 1
- 101700061424 POLB Proteins 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N Penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 241000157426 Pernis Species 0.000 description 1
- HXEACLLIILLPRG-UHFFFAOYSA-N Pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 1
- 230000036660 Plasma protein binding Effects 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N Podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 101700074628 R1A Proteins 0.000 description 1
- 101700054624 RF1 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 101710023872 SERPINA4 Proteins 0.000 description 1
- 102100003803 SERPINA4 Human genes 0.000 description 1
- 101710005026 SPINK6 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229940043230 Sarcosine Drugs 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 229960002175 Thyroglobulin Drugs 0.000 description 1
- 206010043778 Thyroiditis Diseases 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 241000133063 Trixis Species 0.000 description 1
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 1
- 229960005356 Urokinase Drugs 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 229960004355 Vindesine Drugs 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 102000016350 Viral Proteins Human genes 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N [4-[(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenyl] dihydrogen phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000001476 alcoholic Effects 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005257 alkyl acyl group Chemical group 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000845 anti-microbial Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940045698 antineoplastic Taxanes Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000001640 apoptogenic Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- BSJGASKRWFKGMV-UHFFFAOYSA-L azane;dichloroplatinum(2+) Chemical compound N.N.Cl[Pt+2]Cl BSJGASKRWFKGMV-UHFFFAOYSA-L 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- RICLFGYGYQXUFH-UHFFFAOYSA-N buspirone hydrochloride Chemical compound [H+].[Cl-].C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 RICLFGYGYQXUFH-UHFFFAOYSA-N 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2S)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000002612 cardiopulmonary Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 101700075078 cbpG Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000001809 detectable Effects 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 230000001094 effect on targets Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 150000002333 glycines Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 229940121372 histone deacetylase inhibitors Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001861 immunosuppresant Effects 0.000 description 1
- 230000001024 immunotherapeutic Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 101710030587 ligN Proteins 0.000 description 1
- 101700077585 ligd Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000002101 lytic Effects 0.000 description 1
- 238000005710 macrocyclization reaction Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002865 melanocortin Substances 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- WRWNFZAKUHZONV-UHFFFAOYSA-N methanetricarbaldehyde Chemical compound O=CC(C=O)C=O WRWNFZAKUHZONV-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 108091005593 modified peptides Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N n-methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- 229930001140 podophyllotoxin Natural products 0.000 description 1
- 229920002496 poly(ether sulfone) Polymers 0.000 description 1
- 229920003208 poly(ethylene sulfide) Polymers 0.000 description 1
- 229920001601 polyetherimide Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrugs Drugs 0.000 description 1
- 150000003147 proline derivatives Chemical class 0.000 description 1
- 230000036678 protein binding Effects 0.000 description 1
- 238000000575 proteomic Methods 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 108091007521 restriction endonucleases Proteins 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- PHPHRWZFQRLJIA-UZUGEDCSSA-M sodium;(2S,3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;chloride Chemical compound [Na+].[Cl-].OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O PHPHRWZFQRLJIA-UZUGEDCSSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 230000003019 stabilising Effects 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000000576 supplementary Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000001575 tandem quadrupole mass spectrometry Methods 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 1
- 235000008170 thiamine pyrophosphate Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108020003112 toxins Proteins 0.000 description 1
- 108090000464 transcription factors Proteins 0.000 description 1
- 102000003995 transcription factors Human genes 0.000 description 1
- 238000004642 transportation engineering Methods 0.000 description 1
- 108010036927 trypsin-like serine protease Proteins 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000035513 volume of distribution Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- QWCKQJZIFLGMSD-UHFFFAOYSA-N α-Aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N β-Alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
Abstract
Discloses a peptide ligand specific for human Kallikrein comprising a polypeptide comprising at least three reactive groups, separated by at least two loop sequences, and a molecular scaffold which forms covalent bonds with the reactive groups of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold, wherein the loops of the peptide ligand comprise three, four or five, but less than six, amino acids. ops are formed on the molecular scaffold, wherein the loops of the peptide ligand comprise three, four or five, but less than six, amino acids.
Description
Modulation of ured polypeptide specificity
The present invention generally relates to polypeptides which are covalently bound to
lar scaffolds such that two or more peptide loops are subtended between
attachment points to the scaffold. In particular, the invention describes peptides which
are specific for the human protease plasma rein.
Cyclic peptides are able to bind with high affinity and target specificity to protein targets
and hence are an attractive molecule class for the development of therapeutics. In fact,
several cyclic es are already successfully used in the clinic, as for example the
cterial peptide vancomycin, the immunosuppressant drug cyclosporine or the anticancer
drug ocreotide (Driggers, et al., Nat Rev Drug Discov 2008, 7 (7), 608-24). Good
binding properties result from a relatively large interaction surface formed between the
peptide and the target as well as the reduced conformational flexibility of the cyclic
structures. Typically, macrocycles bind to surfaces of several hundred square angstrom,
as for example the cyclic peptide CXCR4 antagonist CVX15 (400 Å2; Wu, B., et al.,
Science 330 (6007), 1066-71), a cyclic peptide with the Arg-Gly-Asp motif binding to
integrin aVb3 (355 Å2) , J. P., et al., Science 2002, 296 (5565), 151-5) or the cyclic
peptide inhibitor upain-1 binding to urokinase-type plasminogen activator (603 Å2; Zhao,
G., et al., J Struct Biol 2007, 160 (1), 1-10).
Due to their cyclic configuration, peptide ycles are less flexible than linear
peptides, leading to a smaller loss of entropy upon binding to targets and ing in a
higher g affinity. The reduced flexibility also leads to locking target-specific
conformations, increasing binding icity compared to linear peptides. This effect has
been exemplified by a potent and selective inhibitor of matrix metalloproteinase 8, MMP-
8) which lost its selectivity over other MMPs when its ring was opened (Cherney, R. J., et
al., J Med Chem 1998, 41 (11), 1749-51). The favorable g properties achieved
through macrocyclization are even more pronounced in multicyclic peptides having more
than one peptide ring as for example in vancomycin, nisin or actinomycin.
Different research teams have previously tethered polypeptides with cysteine residues to
a synthetic lar structure (Kemp, D. S. and McNamara, P. E., J. Org. Chem, 1985;
Timmerman, P. et al., ChemBioChem, 2005). Meloen and co-workers had used
tris(bromomethyl)benzene and related molecules for rapid and quantitative cyclisation of
multiple e loops onto synthetic scaffolds for structural y of protein surfaces
rman, P. et al., ChemBioChem, 2005). Methods for the generation of candidate
drug compounds wherein said compounds are generated by linking cysteine containing
polypeptides to a molecular scaffold as for example tris(bromomethyl)benzene are
disclosed in and .
/077062 discloses a method of selecting a candidate drug compound. In
particular, this nt discloses various scaffold molecules comprising first and
second reactive groups, and contacting said scaffold with a further le to form at
least two linkages between the scaffold and the further molecule in a coupling reaction.
WO2006/078161 discloses binding compounds, immunogenic compounds and
peptidomimetics. This document discloses the artificial synthesis of various collections of
es taken from existing proteins. These peptides are then combined with a constant
tic peptide having some amino acid changes introduced in order to produce
combinatorial libraries. By ucing this diversity via the chemical linkage to separate
peptides featuring various amino acid changes, an increased opportunity to find the
desired binding activity is provided. Figure 1 of this document shows a schematic
entation of the synthesis of various loop peptide constructs. The ucts
sed in this document rely on –SH functionalised peptides, typically comprising
cysteine residues, and heteroaromatic groups on the scaffold, typically comprising
benzylic halogen tuents such as bis- or tris-bromophenylbenzene. Such groups
react to form a thioether linkage between the peptide and the ld.
We recently developed a phage display-based combinatorial approach to generate and
screen large libraries of bicyclic peptides to targets of interest (Heinis, et al., Nat Chem
Biol 2009, 5 (7), 502-7; see also international patent application WO2009/098450).
y, combinatorial libraries of linear peptides containing three cysteine residues and
two regions of six random amino acids (Cys-(Xaa)6-Cys-(Xaa)6-Cys) were displayed on
phage and cyclised by covalently linking the cysteine side chains to a small molecule
(tris-(bromomethyl)benzene). Bicyclic peptides isolated in affinity selections to the human
proteases cathepsin G and plasma Kallikrein (PK) had nanomolar inhibitory constants.
The best inhibitor, PK15, inhibits human PK (hPK) with a Ki of 3 nM. Similarities in the
amino acid sequences of several ed bicyclic peptides suggested that both peptide
loops contribute to the binding. PK15 did not inhibit rat PK (81% sequence identity) nor
the homologous human serine proteases factor XIa (hfXIa; 69% sequence identity) or
thrombin (36% sequence identity) at the highest tration tested (10 mM) (Heinis, et
al., Nat Chem Biol 2009, 5 (7), 502-7). This g suggested that the bicyclic inhibitor is
highly specific and that other human trypsin-like serine proteases will not be inhibited. A
synthetic, small ic inhibitor such as PK15 having the above described potency and
target ivity has ial application as a therapeutic to control PK activity in
hereditary angioedema, a life-threatening disease which is characterized by recurrent
episodes of edema or to t contact activation in cardiopulmonary bypass surgery.
The peptide PK15 was isolated from a y based on the peptide PK2, HACSDRFRNCPLWSGTCG-NH2
, in which the second 6-amino acid loop was randomised.
The sequence of PK15 was H-ACSDRFRNCPADEALCG-NH2, and the IC50 binding
constant for human Kallikrein was 1.7 nM.
y of the Invention
We have analysed the specificity of structured polypeptides selected against human
Kallikrein from a number of libraries with different loop lengths. As a , we have
succeeded in isolating structured peptides capable of binding Kallikrein with improved
binding specificities; and/or which at least provide the public with a useful choice.
In a first aspect, there is ed a peptide ligand specific for human Kallikrein
comprising a polypeptide comprising at least three reactive groups, separated by at least
two loop sequences, and a molecular scaffold which forms covalent bonds with the
reactive groups of the polypeptide such that at least two polypeptide loops are formed on
the molecular scaffold, wherein the loops of the peptide ligand comprise three, four or
five, but less than six, amino acids.
Surprisingly, we have found that peptides comprising less than 6 amino acids in each
loop can have a much higher binding affinity for Kallikrein. For example, the 5x5 peptides
described herein achieve binding constants of 0.08nM or less.
In one embodiment, the loops of the peptide ligand comprise three amino acids and the
polypeptide has the consensus sequence rRVxGr, wherein Gr is a reactive group.
For example, the polypeptide may be one of the polypeptides set forth in Table 3.
In another embodiment, the loops of the peptide ligand comprise five amino acids and a
first loop comprises the consensus sequence GrGGxxNGr, wherein Gr is a ve group.
For example, two adjacent loops of the polypeptide may comprise the consensus
sequence GrGGxxNGrRxxxxGr.
For example, the polypeptide may be one of the peptides set forth in Table 4.
In one embodiment, the loops of the peptide ligand se five amino acids and a first
loop comprises the motif GrxW/FPxK/RGr, wherein Gr is a reactive group. In the present
context, the reference to a “first” loop does not necessarily denote a particular position of
the loop in a sequence. In some embodiments, however, the first loop may be proximal
loop in an amino us to carboxy terminus peptide ce. For example, the
polypeptide further comprises a second, distal loop which comprises the motif
GrT/LHQ/TxLGr. Examples of sequences of the first loop include G Gr, GrxWPSRGr,
GrxFPFRGr and RGr. In these examples, x may be any amino acid, but is for
example S or R.
In one embodiment, the loops of the peptide ligand comprise five amino acids and a first
loop comprises the motif GrxHxDLGr, n Gr is a reactive group.
In one embodiment, the loops of the peptide ligand se five amino acids and a first
loop comprises the motif GrTHxxLGr, wherein Gr is a reactive group.
In one ment, the polypeptide comprises two adjacent loops which comprise the
motif GrxW/FPxK/RGrT/LHQ/TDLGr.
We have shown that the nature of certain positions can influence other positions in the
sequence. In particular, experiments conducted with peptides 06-34 and 0603
demonstrate that positions 1 and 6 influence position 4. Preferably, position 4 is A only if
positions 1 and 6 are S and T respectively.
In the examples herein, numbering refers to the positions in the loops, and ignores the
reactive groups. Thus, in GrxW/FPxK/RGrT/LHQ/TDLGr, x is in position 1 and T/ L in position 6.
For example, the polypeptide may be one of the polypeptides set forth in Table 4, Table 5
or Table 6.
For example, the ptide ligand may comprise one of the polypeptides set forth in
one of Tables 4 to 6.
In the ing embodiments, the reactive group is preferably a reactive amino acid.
Preferably, the reactive amino acid is cysteine.
Variants of the polypeptides according to this aspect of the invention can be prepared as
bed above, by fying those residues which are available for mutation and
preparing libraries which include mutations at those positions. For example, the
polypeptide 06-56 in Table 4 can be mutated without loss of activity at positions Q4 and
T10 (see Examples below). Polypeptide ligands comprising mutations at these positions
can be selected which have improved binding activity in comparison with 06-56.
In a r aspect, there is provided a polypeptide ligand according to the ing
aspect of the invention, which comprises one or more non-natural amino acid
substituents and is resistant to protease degradation.
We have found that certain non-natural amino acids permit binding to plasma Kallikrein
with nM Ki, whilst increasing residence time in plasma icantly.
In one embodiment, the tural amino acid is selected from N-methyl Arginine,
homo-arginine and hydroxyproline. Preferably, N-methyl and homo-derivatives of
Arginine are used to replace ne, and proline 3 can be preferably replaced by
hydroxyproline, azetidine carboxylic acid, or an alpha-substituted amino acid, such as
aminoisobutyric acid. In another embodiment, ne may be replaced with guanidylphenylalanine.
In one embodiment, the polypeptide comprises a first loop which comprises the motif
GrxWPARGr, wherein P is replaced with azetidine carboxylic acid; and/or R is replaced
with N-methyl arginine; and/or R is replaced with homoarginine; and/or R is replaced with
guanidyl-phenylalanine.
In one embodiment, the polypeptide comprises a first loop which comprises the motif
GrxFPYRGr, wherein R is ed with yl arginine; and/or R is replaced with
homoarginine, and wherein proline is replaced by azetidine carboxylic acid; and/or R is
replaced with guanidyl-phenylalanine.
Certain statements that appear below are broader than what appears in the statements of
the invention above. These statements are ed in the sts of providing the
reader with a better understanding of the invention and its practice. The reader is directed
to the accompanying claim set which defines the scope of the invention.
Also described is a method for producing a mutant polypeptide ligand to produce an
improved level of binding activity for a target over that of a parent polypeptide ligand,
wherein the parent polypeptide ligand comprises a polypeptide comprising at least three
ve , separated by at least two loop sequences, and a molecular scaffold
which forms covalent bonds with the reactive groups of the polypeptide such that at least
two polypeptide loops are formed on the molecular scaffold, comprising the steps of: (a)
for each of two or more amino acid positions in each of the loop sequences, producing n
different ies of mutants, each library consisting of parent polypeptides in which one
of said amino acid positions in the loop sequence has been mutated by replacement with
one of n different non-parental amino acids; (b) ing each library for binding to the
parental target, and scoring each mutation; (c) identifying the amino acid positions at
which mutations are tolerated; (d) producing one or more mutant polypeptides comprising
one or more ons located at the amino acid positions identified in step (c).
In one embodiment, step (d) comprises preparing a library comprising polypeptides which
incorporate mutations at two or more of the amino acid positions identified in step (c), and
screening the y for polypeptides with an improved level of binding activity for the
target.
The value of n can be selected according to the number of ent mutants it is ed
to create in each library. For example, if mutants comprising all possible natural amino
acids are desired, n can be 20. If non-natural amino acids are included, such as N-
methylated amino acids, n can be greater than 20, such as 22 or 23. For example, n can
be 2 or more; 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.
Also described is a library of ptide s, wherein the ptide ligands
comprise a polypeptide comprising at least three reactive groups, separated by at least
two loop sequences, and a molecular scaffold which forms covalent bonds with the
reactive groups of the polypeptide such that at least two polypeptide loops are formed on
the lar scaffold, said library consisting of m different mutants of a polypeptide
ligand in which a defined amino acid position in the loop sequences has been mutated by
replacement with one of m different amino acids, wherein m is at least 2.
Also described is a set of libraries of ptide ligands, wherein the polypeptide ligands
se a polypeptide comprising at least three reactive groups, separated by at least
two loop sequences, and a molecular scaffold which forms covalent bonds with the
reactive groups of the polypeptide such that at least two polypeptide loops are formed on
the molecular scaffold, which set comprises two or more ies of polypeptide ligands,
each of said libraries of polypeptide ligands consisting of m different mutants of a
polypeptide ligand in which a defined amino acid position in the loop sequences has been
mutated by replacement with one of m different amino acids.
Preferably, m is between 2 and 20; in embodiments, m is at least 3, 4, 5, 6, 7, 8, 9, 10,
11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or more, as set out in respect of n above.
Also described is a peptide ligand comprising a polypeptide comprising at least three
reactive groups, separated by at least two loop sequences, and a molecular scaffold
which forms covalent bonds with the reactive groups of the polypeptide such that at least
two polypeptide loops are formed on the lar scaffold, wherein the peptide is
modified by the incorporation of at least one non-natural amino acid.
Preferably, the peptide ligand as described is protease-resistant. The non-natural amino
acid substitution(s) increase the level of protease resistance of the polypeptide.
In one embodiment, the non-natural amino acid is selected from N-methyl Arginine,
homo-arginine and ine carboxylic acid and guanidylphenylalanine. Preferably, N-
methyl and homo-derivatives of Arginine are used to replace Arginine, and azetidine
carboxylic acid replaces proline. In another embodiment, Arginine may be replaced with
guanidyl-phenylalanine.
Brief description of the figures
Figure 1 Phage selection of ic peptides. (a) Bicyclic peptide phage libraries.
Random amino acids are indicated as 'X', alanine as 'A' and the constant three cysteine
residues as 'C'. (b) Format of chemically synthesized bicyclic peptide structures having
loops of 3, 5 or 6 amino acids. The structures are generated by linking linear peptides via
three cysteine side chains to tris-(bromomethly)benzene . Amino acids that vary
in the ic es are indicated with 'Xaa'. (c-e) Sequences of bicyclic peptides
isolated from library 5x5 (c), library 3x3 A (d) and library 3x3 B (e). Similarities in amino
acids are highlighted by shading.
Figure 2 Comparison of the surface amino acids of hPK and homologous serine
proteases. (a) Structure of hPK (PDB entry 2ANW) with surface representation. Atoms of
amino acids being exposed to the surface and closer than 4, 8 and 12 Å to idine
(in grey) bound to the S1 pocket are stained more darkly. (b) Structure of hPK. The side
chains of amino acids that are different in hfXIa are highlighted. (c) Structure of hPK. The
side chains of amino acids that are different in rPK are highlighted.
Figure 3 Pictorial representation of the method used for determination of red
residues for on in ptide ligands.
Figure 4 Analysis of amino acid substitutions in peptide 06-34 (Table 4) on the binding of
the e to plasma Kallikrein at 2nM. For each position, the effect of various mutations
at that on is shown, in comparison to the parent sequence.
Figure 5 Analysis of amino acid substitutions in e 06-56 (Table 4) on the binding of
the peptide to plasma Kallikrein at 2nM. For each position, the effect of various mutations
at that position is shown, in comparison to the parent sequence.
Figure 6 Analysis of amino acid tutions in peptide 06-56 (Table 4) on the binding of
the peptide to plasma Kallikrein at 10nM. For each position, the effect of various
mutations at that position is shown, in comparison to the parent sequence.
Figure 7 Mass spec output g the mass spectra of Ac34-18(TMB)-NH2 after
exposure to 35% rat plasma, at t0, 1 day, 2 days and 3 days (method 1). Mass
accuracies vary somewhat due to interfering ions and low concentrations of fragments;
however identification of discrete proteolytic fragments is possible.
Figure 8 Chemical structures of metabolites M1, M2, M3 of Ac34-18(TMB)-NH2
identified after exposure to rat plasma.
Figure 9 Chemical structure of the Ac34-18(TMB)-NH2 lead
Figure 10 Enzyme inhibition assay of Kallikrein by the 34-18(TMB)-NH2 lead and
its 1st loop scrambled derivatives. A dramatic reduction in ty is observed, underlining
the importance of the integrity of the WPAR pharmacophore.
Figure 11 al structures of arginine and its analogues.
Figure 12 Chemical structures of Trp and potential hydrophobic analogues
Figure 13 Chemical structures of Pro and potential constrained analogues
Figure 14 ative Kallikrein inhibition by Aze3, NMeArg5 and doubly modified Ac-
0618(TMB)-NH2.
Figure 15 Chemical structures of Alanine and derivatives thereof
Figure 16 Comparative Kallikrein tion by F2Y4, F2Y2 HR5 and doubly modified Ac-
0618(TMB)-NH2.
Figure 17 Human plasma Kallikrein binding of particular motifs at positions 2, 3, 4 & 5
(with positions 1, 6, 7, 8, 9 &10 fixed to those of 0603).
Detailed Description of the Invention
Unless defined otherwise, all technical and scientific terms used herein have the same
meaning as commonly understood by those of ordinary skill in the art, such as in the arts
of peptide chemistry, cell culture and phage display, nucleic acid chemistry and
biochemistry. Standard techniques are used for molecular biology, genetic and
biochemical methods (see Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd
ed., 2001, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Ausubel et al.,
Short Protocols in Molecular Biology (1999) 4th ed., John Wiley & Sons, Inc.), which are
incorporated herein by reference.
A peptide ligand, as referred to , refers to a peptide covalently bound to a
molecular scaffold. Typically, such peptides comprise two or more ve groups which
are capable of g covalent bonds to the scaffold, and a sequence subtended
between said reactive groups which is referred to as the loop sequence, since it forms a
loop when the peptide is bound to the scaffold. In the present case, the peptides
comprise at least three reactive groups, and form at least two loops on the scaffold.
The reactive groups are groups capable of forming a covalent bond with the molecular
scaffold. lly, the reactive groups are present on amino acid side chains on the
e. Examples are amino-containing groups such as cysteine, lysine and
selenocysteine.
Specificity, in the context herein, refers to the ability of a ligand to bind or otherwise
interact with its cognate target to the exclusion of entities which are similar to the target.
For example, specificity can refer to the ability of a ligand to inhibit the interaction of a
human enzyme, but not a homologous enzyme from a different species. Using the
approach described , specificity can be ted, that is sed or sed,
so as to make the ligands more or less able to ct with homologues or gues of
the ed target. Specificity is not intended to be synonymous with ty, affinity or
avidity, and the potency of the action of a ligand on its target (such as, for example,
binding affinity or level of inhibition) are not necessarily related to its specificity.
Binding activity, as used herein, refers to quantitative binding measurements taken from
g assays, for e as described herein. Therefore, binding ty refers to the
amount of peptide ligand which is bound at a given target concentration.
Multispecificity is the ability to bind to two or more targets. Typically, g peptides are
capable of binding to a single target, such as an epitope in the case of an antibody, due
to their conformational properties. However, peptides can be developed which can bind
to two or more targets; dual specific antibodies, for example, as known in the art as
referred to above. In the present invention, the peptide ligands can be capable of binding
to two or more targets and are therefore be multispecific. Preferably, they bind to two
targets, and are dual specific. The binding may be independent, which would mean that
the binding sites for the targets on the peptide are not structurally hindered by the binding
of one or other of the targets. In this case both targets can be bound independently.
More generally it is expected that the binding of one target will at least partially impede
the binding of the other.
There is a fundamental difference between a dual specific ligand and a ligand with
specificity which encompasses two related targets. In the first case, the ligand is specific
for both targets individually, and interacts with each in a specific manner. For example, a
first loop in the ligand may bind to a first target, and a second loop to a second . In
the second case, the ligand is ecific because it does not differentiate between the
two targets, for example by interacting with an epitope of the targets which is common to
both.
In the context of the present invention, it is possible that a ligand which has ty in
respect of, for example, a target and an orthologue, could be a ific ligand.
However, in one embodiment the ligand is not bispecific, but has a less precise specificity
such that it binds both the target and one or more orthologues. In general, a ligand which
has not been selected t both a target and its orthologue is less likely to be
bispecific as a result of modulation of loop .
If the ligands are truly ific, in one embodiment at least one of the target specificities
of the ligands will be common amongst the ligands selected, and the level of that
specificity can be modulated by the methods disclosed herein. Second or further
specificities need not be shared, and need not be the t of the procedures set forth
herein.
A target is a molecule or part thereof to which the peptide ligands bind or otherwise
interact with. Although binding is seen as a prerequisite to activity of most kinds, and
may be an activity in itself, other activities are envisaged. Thus, the present ion
does not require the measurement of binding directly or indirectly.
The molecular scaffold is any molecule which is able to connect the peptide at le
points to impart one or more structural features to the e. It is not a cross-linker, in
that it does not merely replace a disulphide bond; instead, it provides two or more
attachment points for the peptide. Preferably, the molecular scaffold comprises at least
three ment points for the peptide, referred to as scaffold reactive groups. These
groups are capable of reacting to the ve groups on the peptide to form a covalent
bond. Preferred structures for molecular scaffolds are described below.
Screening for g activity (or any other desired activity) is conducted according to
methods well known in the art, for instance from phage display technology. For example,
targets immobilised to a solid phase can be used to identify and isolate binding members
of a repertoire. Screening allows selection of members of a repertoire according to
d characteristics.
The term library refers to a e of heterogeneous polypeptides or nucleic acids. The
library is composed of members, which are not identical. To this extent, library is
synonymous with oire. ce differences between library members are
responsible for the diversity present in the y. The library may take the form of a
simple mixture of polypeptides or nucleic acids, or may be in the form of organisms or
cells, for example ia, viruses, animal or plant cells and the like, transformed with a
y of nucleic acids. Preferably, each individual organism or cell contains only one or a
limited number of y members.
In one embodiment, the nucleic acids are incorporated into expression vectors, in order to
allow expression of the polypeptides encoded by the nucleic acids. In a preferred
embodiment, therefore, a y may take the form of a population of host organisms,
each organism containing one or more copies of an expression vector containing a single
member of the library in nucleic acid form which can be expressed to produce its
corresponding polypeptide member. Thus, the population of host organisms has the
potential to encode a large repertoire of genetically diverse polypeptide variants.
In one embodiment, a library of nucleic acids encodes a repertoire of polypeptides. Each
nucleic acid member of the library preferably has a ce related to one or more
other members of the y. By related sequence is meant an amino acid sequence
having at least 50% identity, for example at least 60% identity, for example at least 70%
identity, for example at least 80% identity, for example at least 90% identity, for example
at least 95% identity, for example at least 98% ty, for example at least 99% identity
to at least one other member of the y. Identity can be judged across a contiguous
segment of at least 3 amino acids, for example at least 4, 5, 6, 7, 8, 9 or 10 amino acids,
for e least 12 amino acids, for example least 14 amino acids, for example least 16
amino acids, for example least 17 amino acids or the full length of the reference
sequence.
A repertoire is a collection of ts, in this case polypeptide variants, which differ in
their sequence. Typically, the location and nature of the reactive groups will not vary, but
the sequences forming the loops between them can be randomised. Repertoires differ in
size, but should be considered to comprise at least 102 members. Repertoires of 1011 or
more members can be constructed.
A set of polypeptide ligands, as used herein, refers to a plurality of polypeptide ligands
which can be subjected to selection in the methods described. Potentially, a set can be a
repertoire, but it may also be a small collection of polypeptides, from at least 2 up to 10,
, 50, 100 or more.
A group of polypeptide ligands, as used herein, refers to two or more ligands. In one
embodiment, a group of ligands comprises only ligands which share at least one target
specificity. lly, a group will consist of from at least 2, 3, 4, 5, 6, 7, 8, 9 or 10, 20, 50,
100 or more ligands. In one embodiment, a group consists of 2 ligands.
(A) Construction of Peptide Ligands
(i) lar scaffold
Molecular scaffolds are described in, for example, WO2009098450 and nces cited
therein, particularly WO2004077062 and WO2006078161.
As noted in the foregoing documents, the molecular scaffold may be a small molecule,
such as a small organic molecule.
In one ment the molecular scaffold may be, or may be based on, natural
monomers such as nucleosides, sugars, or steroids. For example the molecular scaffold
may comprise a short polymer of such es, such as a dimer or a trimer.
In one embodiment the molecular scaffold is a compound of known toxicity, for e
of low toxicity. Examples of suitable compounds e cholesterols, nucleotides,
steroids, or existing drugs such as tamazepam.
In one embodiment the molecular scaffold may be a macromolecule. In one embodiment
the molecular scaffold is a macromolecule composed of amino acids, nucleotides or
carbohydrates.
In one embodiment the molecular scaffold comprises reactive groups that are capable of
ng with functional group(s) of the polypeptide to form covalent bonds.
The molecular scaffold may comprise chemical groups as amines, thiols, alcohols,
ketones, aldehydes, nitriles, carboxylic acids, esters, s, alkynes, azides,
anhydrides, succinimides, maleimides, alkyl halides and acyl halides.
In one embodiment, the molecular scaffold may comprise or may consist of
tris(bromomethyl)benzene, especially 1,3,5-Tris(bromomethyl)benzene ’), or a
derivative thereof.
In one embodiment, the molecular scaffold is 2,4,6-Tris(bromomethyl)mesitylene. It is
similar to 1,3,5-Tris(bromomethyl)benzene but contains additionally three methyl groups
ed to the e ring. This has the advantage that the additional methyl groups
may form further ts with the polypeptide and hence add additional structural
constraint.
The molecular scaffold useful in the invention contains chemical groups that allow
onal groups of the polypeptide of the encoded y described herein to form
covalent links with the molecular scaffold. Said chemical groups are selected from a wide
range of functionalities including amines, thiols, alcohols, s, aldehydes, nitriles,
carboxylic acids, esters, alkenes, alkynes, anhydrides, succinimides, maleimides, azides,
alkyl halides and acyl s.
(ii) Polypeptide
The reactive groups of the polypeptides can be provided by side chains of natural or nonnatural
amino acids. The reactive groups of the ptides can be selected from thiol
groups, amino groups, carboxyl groups, guanidinium groups, phenolic groups or hydroxyl
groups. The reactive groups of the polypeptides can be selected from azide, keto-
carbonyl, , vinyl, or aryl halide groups. The reactive groups of the polypeptides for
linking to a molecular scaffold can be the amino or carboxy termini of the polypeptide.
In some embodiments each of the reactive groups of the polypeptide for linking to a
molecular scaffold are of the same type. For example, each reactive group may be a
cysteine e. r s are provided in WO2009098450.
In some embodiments the reactive groups for g to a molecular scaffold may
comprise two or more different types, or may comprise three or more different types. For
example, the reactive groups may comprise two cysteine residues and one lysine
residue, or may comprise one cysteine residue, one lysine residue and one N-terminal
amine.
Cysteine can be employed because it has the advantage that its reactivity is most
different from all other amino acids. Scaffold reactive groups that could be used on the
molecular scaffold to react with thiol groups of cysteines are alkyl halides (or also named
halogenoalkanes or haloalkanes). Examples are bromomethylbenzene (the ld
reactive group exemplified by TBMB) or iodoacetamide. Other scaffold reactive goups
that are used to couple selectively compounds to nes in ns are maleimides.
Examples of maleimides which may be used as molecular scaffolds include: tris-(2-
maleimidoethyl)amine, tris-(2-maleimidoethyl)benzene, tris-(maleimido)benzene.
Selenocysteine is also a natural amino acid which has a similar reactivity to cysteine and
can be used for the same reactions. Thus, wherever cysteine is mentioned, it is typically
acceptable to substitute cysteine unless the context suggests otherwise.
Lysines (and primary amines of the N-terminus of peptides) are also suited as reactive
groups to modify peptides on phage by linking to a molecular scaffold. However, they are
more abundant in phage ns than cysteines and there is a higher risk that phage
particles might become cross-linked or that they might lose their ivity. Nevertheless,
it has been found that s are especially useful in intramolecular reactions (e.g. when
a molecular scaffold is already linked to the phage peptide) to form a second or
consecutive linkage with the molecular scaffold. In this case the lar scaffold reacts
preferentially with lysines of the displayed peptide (in particular lysines that are in close
proximity). ld reactive groups that react selectively with primary amines are
succinimides, des or alkyl halides. In the bromomethyl group that is used in a
number of the accompanying examples, the electrons of the benzene ring can stabilize
the cationic transition state. This particular aryl halide is therefore 100-1000 times more
reactive than alkyl halides. Examples of succinimides for use as molecular scaffold
include tris-(succinimidyl riacetate), 1,3,5-Benzenetriacetic acid. Examples of
aldehydes for use as molecular scaffold include Triformylmethane. Examples of alkyl
halides for use as molecular scaffold include 1,3,5-Tris(bromomethyl)-2,4,6-
trimethylbenzene, 1,3,5-Tris(bromomethyl) e, 1,3,5-Tris(bromomethyl)-2,4,6-
triethylbenzene.
The amino acids with reactive groups for linking to a molecular scaffold may be d at
any suitable positions within the polypeptide. In order to influence the particular
structures or loops created, the positions of the amino acids having the reactive groups
may be varied by the skilled operator, e.g. by manipulation of the nucleic acid encoding
the polypeptide in order to mutate the polypeptide ed. By such means, loop length
can be manipulated in accordance with the t teaching.
For example, the polypeptide can comprise the sequence AC(X)nC(X)mCG, wherein X
stands for a random natural amino acid, A for alanine, C for cysteine and G for glycine
and n and m, which may be the same or different, are s between 3 and 6.
(iii) Reactive groups of the polypeptide
The molecular scaffold useful in the invention may be bonded to the polypeptide via
functional or reactive groups on the polypeptide. These are typically formed from the side
chains of particular amino acids found in the polypeptide r. Such ve groups
may be a cysteine side chain, a lysine side chain, or an N-terminal amine group or any
other suitable reactive group. Again, details may be found in WO2009098450.
Examples of reactive groups of natural amino acids are the thiol group of cysteine, the
amino group of lysine, the carboxyl group of aspartate or glutamate, the guanidinium
group of arginine, the phenolic group of ne or the hydroxyl group of . Nonnatural
amino acids can provide a wide range of reactive groups including an azide, a
keto-carbonyl, an alkyne, a vinyl, or an aryl halide group. The amino and carboxyl group
of the termini of the polypeptide can also serve as reactive groups to form covalent bonds
to a molecular scaffold/molecular core.
The ptides of the invention contain at least three reactive groups. Said
polypeptides can also contain four or more reactive groups. The more reactive groups are
used, the more loops can be formed in the molecular scaffold.
In a preferred embodiment, polypeptides with three reactive groups are generated.
Reaction of said polypeptides with a molecular scaffold/molecular core having a three-
fold rotational symmetry generates a single product isomer. The tion of a single
product isomer is favourable for several s. The nucleic acids of the compound
ies encode only the primary sequences of the polypeptide but not the isomeric state
of the molecules that are formed upon reaction of the polypeptide with the lar
core. If only one product isomer can be formed, the assignment of the nucleic acid to the
product isomer is clearly defined. If multiple t s are formed, the nucleic acid
can not give information about the nature of the product isomer that was isolated in a
screening or selection process. The formation of a single product isomer is also
advantageous if a specific member of a library is synthesized. In this case, the chemical
reaction of the polypeptide with the molecular scaffold yields a single t isomer
rather than a mixture of isomers.
In another embodiment of the invention, polypeptides with four reactive groups are
generated. Reaction of said polypeptides with a molecular scaffold/molecular core having
a tetrahedral symmetry generates two product isomers. Even though the two different
product isomers are encoded by one and the same nucleic acid, the isomeric nature of
the isolated isomer can be determined by chemically synthesizing both s,
separating the two isomers and testing both isomers for binding to a target ligand.
In one embodiment of the invention, at least one of the reactive groups of the
polypeptides is orthogonal to the remaining reactive groups. The use of orthogonal
reactive groups allows the directing of said orthogonal reactive groups to specific sites of
the molecular core. Linking strategies ing orthogonal reactive groups may be used
to limit the number of t isomers formed. In other words, by choosing distinct or
different reactive groups for one or more of the at least three bonds to those chosen for
the remainder of the at least three bonds, a particular order of bonding or directing of
specific reactive groups of the polypeptide to specific positions on the molecular scaffold
may be usefully achieved.
In r embodiment, the ve groups of the polypeptide of the invention are
reacted with molecular linkers wherein said linkers are capable to react with a lar
ld so that the linker will intervene between the molecular scaffold and the
polypeptide in the final bonded state.
In some embodiments, amino acids of the members of the libraries or sets of
polypeptides can be replaced by any natural or non-natural amino acid. Excluded from
these exchangeable amino acids are the ones harbouring functional groups for crosslinking
the polypeptides to a molecular core, such that the loop sequences alone are
exchangeable. The exchangeable polypeptide sequences have either random
sequences, constant sequences or sequences with random and constant amino acids.
The amino acids with reactive groups are either located in defined positions within the
polypeptide, since the on of these amino acids determines loop size.
In one embodiment, an polypeptide with three reactive groups has the sequence
(X)lY(X)mY(X)nY(X)o, wherein Y represents an amino acid with a reactive group, X
represents a random amino acid, m and n are numbers between 3 and 6 defining the
length of intervening polypeptide segments, which may be the same or different, and l
and o are numbers between 0 and 20 defining the length of flanking polypeptide
segments.
Alternatives to thiol-mediated conjugations can be used to attach the lar scaffold
to the peptide via covalent interactions. Alternatively these techniques may be used in
modification or attachment of further moieties (such as small molecules of interest which
are distinct from the molecular scaffold) to the polypeptide after they have been selected
or isolated as bed herein – in this embodiment then clearly the attachment need not
be covalent and may embrace non-covalent ment. These methods may be used
instead of (or in combination with) the thiol mediated methods by producing phage that
y proteins and peptides bearing unnatural amino acids with the requisite chemical
ve groups, in combination small molecules that bear the complementary reactive
group, or by incorporating the unnatural amino acids into a chemically or recombinantly
synthesised polypeptide when the molecule is being made after the selection/isolation
phase. Further details can be found in WO2009098450 or , et al., Nat Chem Biol
2009, 5 (7), 502-7.
(iv) Combination of loops to form multispecific molecules
Loops from peptide ligands, or repertoires of peptide ligands, are advantageously
combined by cing and de novo synthesis of a polypeptide incorporating the
combined loops. atively, nucleic acids encoding such polypeptides can be
synthesised.
Where repertoires are to be combined, particularly single loop repertoires, the nucleic
acids encoding the oires are advantageously digested and re-ligated, to form a
novel repertoire having ent combinations of loops from the constituent repertoires.
Phage vectors can include nkers and other sites for ction enzymes which can
provide unique points for cutting and relegation the vectors, to create the desired
multispecific peptide ligands. Methods for manipulating phage libraries are well known in
respect of dies, and can be applied in the present case also.
(v) Attachment of Effector Groups and Functional Groups
Effector and/or onal groups can be attached, for example, to the N or C termini of
the polypeptide, or to the molecular scaffold.
riate effector groups include antibodies and parts or fragments thereof. For
instance, an effector group can include an antibody light chain constant region (CL), an
antibody CH1 heavy chain , an antibody CH2 heavy chain domain, an antibody
CH3 heavy chain domain, or any combination thereof, in addition to the one or more
constant region domains. An effector group may also comprise a hinge region of an
antibody (such a region normally being found between the CH1 and CH2 domains of an
IgG molecule).
In a further preferred embodiment, an effector group ing is an Fc region of an IgG
molecule. Advantageously, a peptide ligand-effector group as described herein
comprises or consists of a peptide ligand Fc fusion having a tb ife of a day or more,
two days or more, 3 days or more, 4 days or more, 5 days or more, 6 days or more or 7
days or more. Most advantageously, the peptide ligand according to the present invention
comprises or consists of a e ligand Fc fusion having a tb half-life of a day or more.
Functional groups include, in general, binding , drugs, reactive groups for the
attachment of other entities, functional groups which aid uptake of the macrocyclic
peptides into cells, and the like.
The ability of peptides to penetrate into cells will allow peptides against intracellular
targets to be effective. Targets that can be accessed by es with the ability to
penetrate into cells include transcription factors, intracellular signalling les such as
tyrosine kinases and molecules involved in the apoptotic pathway. Functional groups
which enable the penetration of cells include peptides or chemical groups which have
been added either to the peptide or the molecular scaffold. Peptides such as those
derived from such as VP22, HIV-Tat, a homeobox protein of Drosophila (Antennapedia),
e.g. as described in Chen and Harrison, mical Society ctions (2007)
Volume 35, part 4, p821 "Cell-penetrating peptides in drug development: enabling
intracellular s" and “Intracellular delivery of large molecules and small peptides by
cell penetrating peptides” by Gupta et al. in ed Drug Discovery Reviews (2004)
Volume 57 9637. Examples of short peptides which have been shown to be efficient at
translocation through plasma membranes include the 16 amino acid penetratin peptide
from Drosophila Antennapedia n (Derossi et al (1994) J Biol. Chem. Volume 269
p10444 ‘’The third helix of the Antennapedia homeodomain ocates through
ical membranes’’), the 18 amino acid ‘model amphipathic peptide’ (Oehlke et al
(1998) Biochim Biophys Acts Volume 1414 p127 “Cellular uptake of an alpha-helical
amphipathic model peptide with the potential to deliver polar compounds into the cell
interior non-endocytically’’) and arginine rich regions of the HIV TAT protein. Non peptidic
approaches include the use of small molecule mimics or SMOCs that can be easily
ed to biomolecules (Okuyama et al (2007) Nature Methods Volume 4 p153 ‘Smallmolecule
mimics of an a-helix for efficient transport of proteins into cells’. Other chemical
strategies to add inium groups to molecules also enhance cell penetration (Elson-
Scwab et al (2007) J Biol Chem Volume 282 p13585 dinylated Neomcyin Delivers
Large ive Cargo into cells through a heparin Sulphate Dependent Pathway”). Small
molecular weight molecules such as steroids may be added to the molecular scaffold to
enhance uptake into cells.
One class of functional groups which may be attached to peptide ligands includes
antibodies and binding fragments thereof, such as Fab, Fv or single domain fragments.
In particular, antibodies which bind to proteins capable of increasing the half life of the
peptide ligand in vivo may be used.
RGD peptides, which bind to integrins which are present on many cells, may also be
incorporated.
In one embodiment, a peptide ligand-effector group as described has a tb half-life
selected from the group consisting of: 12 hours or more, 24 hours or more, 2 days or
more, 3 days or more, 4 days or more, 5 days or more, 6 days or more, 7 days or more, 8
days or more, 9 days or more, 10 days or more, 11 days or more, 12 days or more, 13
days or more, 14 days or more, 15 days or more or 20 days or more. Advantageously a
peptide ligand-effector group or composition as described will have a tb half life in the
range 12 to 60 hours. In a further embodiment, it will have a t ife of a day or more. In
a further embodiment still, it will be in the range 12 to 26 hours.
Functional groups include drugs, such as cytotoxic agents for cancer therapy. These
include ting agents such as tin and carboplatin, as well as oxaliplatin,
mechlorethamine, cyclophosphamide, mbucil, ifosfamide; Anti-metabolites
including purine s azathioprine and mercaptopurine)) or pyrimidine analogs; plant
alkaloids and terpenoids including vinca alkaloids such as stine, Vinblastine,
lbine and Vindesine; Podophyllotoxin and its tives etoposide and teniposide;
Taxanes, including paclitaxel, originally known as Taxol; omerase inhibitors
including thecins: irinotecan and topotecan, and type II inhibitors including
amsacrine, etoposide, etoposide phosphate, and side. Further agents can include
mour antibiotics which include the immunosuppressant dactinomycin (which is used
in kidney transplantations), doxorubicin, epirubicin, bleomycin and others.
Possible effector groups also include enzymes, for instance such as carboxypeptidase
G2 for use in enzyme/prodrug therapy, where the peptide ligand replaces antibodies in
ADEPT.
(vi) Synthesis
It should be noted that once a polypeptide of interest is isolated or identified as described
herein, then its subsequent synthesis may be simplified wherever possible. Thus, groups
or sets of polypeptides need not be produced by recombinant DNA techniques. For
example, the ce of polypeptides of interest may be determined, and they may be
manufactured synthetically by standard techniques followed by reaction with a molecular
scaffold in vitro. When this is performed, standard chemistry may be used since there is
no longer any need to preserve the functionality or integrity of the genetically encoded
carrier particle, such as phage. This enables the rapid large scale preparation of e
material for r downstream experiments or validation. In this , large scale
preparation of the candidates or leads identified by the methods as described could be
accomplished using conventional chemistry such as that disclosed in Timmerman et al.
Also described is the manufacture of polypeptides or conjugates selected as set out
herein, wherein the manufacture comprises optional further steps as explained below. In
one embodiment, these steps are carried out on the end product polypeptide/conjugate
made by chemical synthesis, rather than on the phage.
Optionally amino acid residues in the polypeptide of interest may be substituted when
manufacturing a conjugate or x e.g. after the initial isolation/identification step.
Peptides can also be extended, to incorporate for example another loop and therefore
introduce multiple specificities.
To extend the peptide, it may simply be extended chemically at its inus or C-
us or within the loops using orthogonally protected lysines (and analogues) using
standard solid phase or solution phase try. Standard protein chemistry may be
used to introduce an activatable N- or C-terminus. atively additions may be made
by fragment condensation or native al ligation e.g. as described in (Dawson PE,
Muir TW, Clark-Lewis I, Kent, SBH. 1994. Synthesis of Proteins by Native Chemical
Ligation. Science 266:776-779), or by enzymes, for example using subtiligase as
described in (Subtiligase: a tool for semisynthesis of proteins Chang TK, Jackson DY,
Burnier JP, Wells JA Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12544-8 or in
Bioorganic & nal Chemistry Letters Tags for labelling protein N-termini with
subtiligase for mics Volume 18, Issue 22, 15 November 2008, Pages 6000-
6003 Tags for labeling protein N-termini with subtiligase for proteomics; Hikari A.I.
Yoshihara, Sami Mahrus and James A. Wells).
Alternatively, the peptides may be extended or modified by further conjugation h
disulphide bonds. This has the onal advantage of allowing the first and second
peptide to dissociate from each other once within the reducing environment of the cell. In
this case, the molecular scaffold (eg. TBMB) could be added during the chemical
synthesis of the first peptide so as to react with the three cysteine groups; a r
cysteine could then be appended to the N-terminus of the first peptide, so that this
cysteine only reacted with a free cysteine of the second peptide.
r techniques apply equally to the synthesis/coupling of two bicyclic and bispecific
macrocycles, potentially creating a tetraspecific molecule.
Furthermore, addition of other functional groups or effector groups may be accomplished
in the same manner, using appropriate chemistry, coupling at the N- or C-termini or via
side . In one embodiment, the coupling is conducted in such a manner that it does
not block the activity of either entity.
(vii) Peptide modification
To develop the bicyclic peptides (Bicycles; peptides conjugated to molecular scaffolds)
into a suitable drug-like molecule, r that be for ion, inhalation, nasal, ocular,
oral or topical administration, a number of ties need considered. The following at
least need to be ed into a given lead Bicycle:
• protease stability, whether this concerns Bicycle ity to plasma proteases,
epithelial ("membrane-anchored") proteases, gastric and intestinal proteases, lung
surface proteases, intracellular proteases and the like. Protease stability should
be maintained between different species such that a e lead candidate can
be developed in animal models as well as administered with ence to
• replacement of oxidation-sensitive residues, such as tryptophan and methionine
with oxidation-resistant analogues in order to improve the ceutical stability
profile of the molecule
• a ble solubility profile, which is a function of the proportion of charged and
hydrophilic versus hydrophobic residues, which is important for formulation and
absorption purposes
• correct balance of charged versus hydrophobic residues, as hydrophobic residues
nce the degree of plasma protein binding and thus the concentration of the
free available fraction in plasma, while charged residues (in particular arginines)
may influence the interaction of the peptide with the phospholipid membranes on
cell es. The two in combination may influence half-life, volume of distribution
and exposure of the peptide drug, and can be tailored according to the al
endpoint. In addition, the correct combination and number of charged versus
hobic residues may reduce irritation at the injection site (were the peptide
drug administered aneously).
• a tailored half-life, depending on the clinical indication and treatment regimen. It
may be prudent to develop an unmodified molecule for short exposure in an acute
illness management setting, or develop a bicyclic peptide with chemical
modifications that enhance the plasma half-life, and hence be optimal for the
ment of more chronic disease states.
ches to stabilise therapeutic peptide candidates against proteolytic degradation
are numerous, and p with the peptidomimetics field (for reviews see Gentilucci et
al, Curr. Pharmaceutical Design, (2010), 16, 3185-203, and Nestor et al, Curr. Medicinal
Chem (2009), 16, 4399-418).
These include
• Cyclisation of peptide
• N- and C-terminal capping, usually N-terminal acetylation and C-terminal
amidation.
• Alanine scans, to reveal and potentially remove the proteolytic attack site(s).
• D-amino acid replacement, to probe the steric requirements of the amino acid side
chain, to increase proteolytic stability by steric hindrance and by a sity of D-
amino acids to stabilise b-turn conformations (Tugyi et al (2005) PNAS, 102(2),
413–418).
• N-methyl/N-alkyl amino acid ement, to impart proteolytic protection by direct
modification of the scissile amide bond (Fiacco et al, Chembiochem. (2008),
9(14), 2200–3). N-methylation also has strong effect on the nal angles of the
peptide bond, and is believed to aid in cell penetration & oral availability (Biron et
al (2008), Angew. Chem. Int. Ed., 47, 2595 –99)
• Incorporation of non-natural amino acids, i.e. by employing
- ric/isoelectronic side chains that are not recognised by
proteases, yet have no effect on target potency
- Constrained amino acid side chains, such that proteolytic hydrolysis of
the nearby peptide bond is conformationally and sterically d. In
particular, these concern proline analogues, bulky ains, Cadisubstituted
derivatives (where the simplest tive is Aib, H2NC
(CH3)2-COOH), and cyclo amino acids, a simple derivative being
amino-cyclopropylcarboxylic acid).
• Peptide bond surrogates, and examples include
- N-alkylation (see above, i.e. CO-NR)
- Reduced peptide bonds (CH2-NH-)
- Peptoids (N-alkyl amino acids, NR-CH2-CO)
- Thio-amides (CS-NH)
- Azapeptides (CO-NH-NR)
- Trans-alkene (RHC=C-)
- Retro-inverso (NH-CO)
- Urea surrogates (NH-CO-NHR)
• e backbone length modulation
- i.e. b2/3- amino acids, (NH-CR-CH2-CO, NH-CH2-CHR-CO),
• Substitutions on the alpha-carbon on amino acids, which constrains ne
conformations, the simplest tive being Aminoisobutyric acid (Aib).
It should be explicitly noted that some of these modifications may also serve to
deliberately improve the y of the e against the target, or, for example to
identify potent substitutes for the oxidation-sensitive amino acids (Trp and Met). It should
also be noted that the Bicycle lead Ac34-18(TMB)-NH2 already harbours two
modifications that impart resistance to proteolytic degradation, these being N/C-terminal
g, and (bi)cyclisation.
(B) Repertoires, sets and groups of polypeptide ligands
(i) Construction of Libraries
Libraries intended for selection may be constructed using techniques known in the art, for
example as set forth in /077062, or biological systems, including phage vector
systems as described herein. Other vector systems are known in the art, and include
other phage (for instance, phage lambda), bacterial plasmid expression vectors,
eukaryotic cell-based expression s, including yeast vectors, and the like. For
example, see WO2009098450 or Heinis, et al., Nat Chem Biol 2009, 5 (7), 502-7.
Non-biological systems such as those set forth in WO2004/077062 are based on
conventional chemical screening ches. They are simple, but lack the power of
biological systems since it is impossible, or at least impracticably onerous, to screen large
libraries of peptide ligands. However, they are useful where, for instance, only a small
number of peptide ligands needs to be screened. Screening by such individual assays,
however, may be time-consuming and the number of unique molecules that can be tested
for binding to a specific target generally does not exceed 106 chemical entities.
In contrast, ical screening or selection methods generally allow the sampling of a
much larger number of different molecules. Thus ical s can be used in
application of the invention. In biological procedures, molecules are assayed in a single
reaction vessel and the ones with favourable properties (i.e. binding) are physically
ted from ve molecules. Selection strategies are ble that allow to
generate and assay simultaneously more than 1013 individual compounds. Examples for
powerful ty selection techniques are phage display, ribosome display, mRNA
display, yeast display, bacterial display or RNA/DNA aptamer methods. These biological
in vitro ion methods have in common that ligand repertoires are encoded by DNA or
RNA. They allow the propagation and the identification of selected ligands by
sequencing. Phage display technology has for e been used for the isolation of
antibodies with very high binding affinities to virtually any target.
When using a biological , once a vector system is chosen and one or more nucleic
acid sequences encoding polypeptides of interest are cloned into the library vector, one
may generate diversity within the cloned molecules by undertaking mutagenesis prior to
expression; alternatively, the d proteins may be sed and selected before
mutagenesis and additional rounds of selection are performed.
Mutagenesis of nucleic acid sequences encoding structurally optimised polypeptides is
carried out by standard molecular methods. Of ular use is the polymerase chain
reaction, or PCR, (Mullis and a (1987) Methods Enzymol., 155: 335, herein
incorporated by reference). PCR, which uses multiple cycles of DNA replication catalysed
by a thermostable, pendent DNA polymerase to amplify the target sequence of
interest, is well known in the art. The uction of various antibody libraries has been
discussed in Winter et al. (1994) Ann. Rev. Immunology 12, 433-55, and references cited
therein.
Alternatively, given the short chain lengths of the polypeptides according to the invention,
the variants are preferably synthesised de novo and inserted into suitable expression
vectors. Peptide synthesis can be carried out by rd techniques known in the art, as
described above. Automated peptide synthesisers are widely available, such as the
Applied Biosystems ABI 433 (Applied tems, Foster City, CA, USA)
(ii) Genetically encoded diversity
In one embodiment, the polypeptides of interest are genetically encoded. This offers the
advantage of enhanced diversity together with ease of handling. An example of a
genetically polypeptide library is a mRNA display library. Another example is a replicable
genetic display package (rgdp) library such as a phage display library. In one
embodiment, the polypeptides of interest are genetically d as a phage display
library.
Thus, in one embodiment the complex comprises a replicable genetic display package
(rgdp) such as a phage particle. In these ments, the nucleic acid can be
comprised by the phage genome. In these embodiments, the polypeptide can be
comprised by the phage coat.
In some embodiments, the invention may be used to produce a genetically encoded
combinatorial library of polypeptides which are generated by translating a number of
c acids into corresponding polypeptides and linking molecules of said molecular
scaffold to said polypeptides.
The genetically encoded combinatorial library of polypeptides may be generated by
phage display, yeast display, ribosome display, bacterial display or mRNA display.
Techniques and ology for ming phage display can be found in
WO2009098450.
In one embodiment, screening may be med by contacting a library, set or group of
polypeptide ligands with a target and isolating one or more member(s) that bind to said
In another embodiment, individual members of said library, set or group are ted
with a target in a screen and members of said library that bind to said target are
identified.
In another embodiment, members of said library, set or group are simultaneously
contacted with a target and members that bind to said target are selected.
The target(s) may be a peptide, a protein, a polysaccharide, a lipid, a DNA or a RNA.
The target may be a receptor, a receptor ligand, an enzyme, a e or a cytokine.
The target may be a prokaryotic protein, a eukaryotic protein, or an archeal n. More
ically the target ligand may be a mammalian protein or an insect protein or a
bacterial protein or a fungal protein or a viral protein.
The target ligand may be an enzyme, such as a protease.
It should be noted that the invention also embraces polypeptide ligands isolated from a
screen as described herein. In one embodiment the ing method(s) further
comprise the step of: manufacturing a quantity of the polypeptide ed as capable of
binding to said targets.
The invention also relates to peptide ligands having more than two loops. For example,
tricyclic polypeptides joined to a molecular ld can be created by joining the N- and
C- termini of a bicyclic polypeptide joined to a molecular scaffold according to the present
invention. In this manner, the joined N and C termini create a third loop, making a
tricyclic polypeptide. This embodiment need not be carried out on phage, but can be
carried out on a polypeptide–molecular scaffold conjugate as bed herein. g
the N- and C- termini is a matter of routine peptide chemistry. In case any ce is
needed, the C-terminus may be activated and/or the N- and C- termini may be extended
for example to add a ne to each end and then join them by disulphide bonding.
Alternatively the joining may be accomplished by use of a linker region incorporated into
the N/C termini. Alternatively the N and C termini may be joined by a conventional
peptide bond. Alternatively any other suitable means for joining the N and C termini may
be employed, for example N-C-cyclization could be done by standard techniques, for
example as disclosed in Linde et al. Peptide Science 90, 671-682 (2008) "Structureactivity
relationship and metabolic stability s of backbone cyclization and N-
ation of melanocortin peptides", or as in Hess et al. J. Med. Chem. 51, 1026-1034
(2008) "backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally
administered drug lead for treating obesity". One advantage of such tricyclic molecules is
the avoidance of proteolytic ation of the free ends, in particular by exoprotease
action. r advantage of a tricyclic polypeptide of this nature is that the third loop
may be utilised for generally applicable functions such as BSA binding, cell entry or
transportation effects, tagging or any other such use. It will be noted that this third loop
will not typically be available for selection (because it is not produced on the phage but
only on the polypeptide-molecular scaffold conjugate) and so its use for other such
biological functions still advantageously leaves both loops 1 and 2 for selection/creation
of specificity.
(iii) Phage purification
Any suitable means for cation of the phage may be used. Standard techniques may
be applied. For example, phage may be purified by filtration or by precipitation such as
PEG itation; phage particles may be produced and purified by polyethylene-glycol
(PEG) precipitation as described previously. Details can be found in WO2009098450.
In case r guidance is needed, reference is made to s et al (Protein
Engineering Design and Selection 2004 17(10):709-713. Selection of optical biosensors
from chemisynthetic antibody libraries.) In one embodiment phage may be purified as
taught therein. The text of this publication is specifically orated herein by reference
for the method of phage purification; in particular reference is made to the materials and
methods n starting part way down the right-column at page 709 of Jespers et al.
Moreover, the phage may be purified as published by Marks et al J.Mol.Biol vol 222
pp581-597, which is specifically incorporated herein by reference for the particular
description of how the phage production/purification is carried out.
(iv) Reaction try
The present disclosure makes use of chemical conditions for the modification of
polypeptides which ageously retain the function and integrity of the genetically
encoded element of the product. Specifically, when the genetically encoded element is a
polypeptide displayed on the surface of a phage encoding it, the chemistry
advantageously does not compromise the ical integrity of the phage. In general,
conditions are set out in WO2009098450.
(C) Use of polypeptide ligands according to the invention
Polypeptide ligands selected according to the method described may be employed in in
vivo therapeutic and prophylactic applications, in vitro and in vivo diagnostic applications,
in vitro assay and t applications, and the like. Ligands having selected levels of
specificity are useful in applications which involve testing in non-human animals, where
reactivity is desirable, or in diagnostic applications, where cross-reactivity with
homologues or paralogues needs to be carefully lled. In some applications, such
as vaccine applications, the ability to elicit an immune response to predetermined ranges
of antigens can be exploited to tailor a vaccine to specific diseases and pathogens.
Substantially pure peptide ligands of at least 90 to 95% homogeneity are preferred for
administration to a mammal, and 98 to 99% or more neity is most preferred for
pharmaceutical uses, especially when the mammal is a human. Once purified, partially or
to homogeneity as d, the selected polypeptides may be used diagnostically or
therapeutically (including extracorporeally) or in developing and performing assay
procedures, immunofluorescent stainings and the like vite and Pernis, (1979 and
1981) Immunological Methods, Volumes I and II, Academic Press, NY).
The peptide ligands of the t invention will typically find use in preventing,
suppressing or treating inflammatory states, allergic hypersensitivity, cancer, bacterial or
viral infection, and autoimmune disorders (which include, but are not d to, Type I
es, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, Crohn's
disease and myasthenia gravis).
In the instant ation, the term "prevention" es administration of the protective
composition prior to the induction of the disease. "Suppression" refers to administration of
the composition after an inductive event, but prior to the al appearance of the
disease. "Treatment" involves administration of the protective composition after disease
symptoms become manifest.
Animal model s which can be used to screen the iveness of the peptide
ligands in protecting against or treating the disease are available. The use of animal
model systems is facilitated by the present invention, which allows the development of
polypeptide ligands which can cross react with human and animal targets, to allow the
use of animal models.
Methods for the testing of systemic lupus matosus (SLE) in susceptible mice are
known in the art (Knight et al. (1978) J Exp. Med., 147: 1653; Reinersten et al. (1978)
New Eng. J : Med., 299: 515). Myasthenia Gravis (MG) is tested in SJL/J female mice by
inducing the disease with soluble AchR protein from another species (Lindstrom et al.
(1988) Adv. Inzn7unol., 42: 233). Arthritis is induced in a susceptible strain of mice by
injection of Type II collagen t et al. (1984) Ann. Rev. l., 42: 233). A model
by which adjuvant arthritis is induced in susceptible rats by injection of cterial heat
shock protein has been described (Van Eden et al. (1988) Nature, 331: 171). Thyroiditis
is induced in mice by administration of thyroglobulin as described (Maron et al. (1980) J.
Exp. Med., 152: 1115). Insulin dependent diabetes mellitus (IDDM) occurs lly or
can be induced in certain strains of mice such as those described by Kanasawa et al.
(1984) Diabetologia, 27: 113. EAE in mouse and rat serves as a model for MS in human.
In this model, the demyelinating disease is induced by administration of myelin basic
protein (see Paterson (1986) Textbook of Immunopathology, Mischer et al., eds., Grune
and Stratton, New York, pp. 3; McFarlin et al. (1973) Science, 179: 478: and Satoh
et al. (1987) J ; Immunol., 138: 179).
lly, the present peptide ligands will be utilised in purified form together with
pharmacologically appropriate carriers. Typically, these carriers include aqueous or
alcoholic/aqueous solutions, emulsions or suspensions, any including saline and/or
buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose,
dextrose and sodium chloride and lactated Ringer's. le physiologically-acceptable
adjuvants, if necessary to keep a polypeptide complex in suspension, may be chosen
from thickeners such as carboxymethylcellulose, nylpyrrolidone, n and
alginates.
Intravenous vehicles include fluid and nutrient replenishers and electrolyte replenishers,
such as those based on Ringer's dextrose. Preservatives and other additives, such as
antimicrobials, antioxidants, ing agents and inert gases, may also be present (Mack
(1982) Remington's ceutical Sciences, 16th Edition).
The peptide ligands of the present invention may be used as tely administered
compositions or in ction with other agents. These can include antibodies, dy
fragments and various immunotherapeutic drugs, such as cylcosporine, methotrexate,
adriamycin or cisplatinum, and toxins. Pharmaceutical compositions can include
"cocktails" of various cytotoxic or other agents in conjunction with the selected antibodies,
receptors or binding proteins f of the present invention, or even combinations of
selected polypeptides according to the present invention having different specificities,
such as polypeptides selected using different target s, whether or not they are
pooled prior to administration.
The route of administration of pharmaceutical compositions as described herein may be
any of those commonly known to those of ordinary skill in the art. For therapy, including
without limitation immunotherapy, the selected antibodies, receptors or binding proteins
thereof of the invention can be administered to any patient in accordance with standard
techniques. The administration can be by any appropriate mode, including parenterally,
intravenously, intramuscularly, intraperitoneally, transdermally, via the pulmonary route,
or also, appropriately, by direct on with a catheter. The dosage and ncy of
administration will depend on the age, sex and condition of the patient, concurrent
administration of other drugs, counterindications and other ters to be taken into
account by the clinician.
The peptide ligands of this invention can be lyophilised for storage and reconstituted in a
suitable carrier prior to use. This technique has been shown to be effective and art-known
lyophilisation and reconstitution techniques can be employed. It will be appreciated by
those skilled in the art that lyophilisation and reconstitution can lead to varying degrees of
activity loss and that use levels may have to be adjusted upward to compensate.
The compositions containing the present peptide ligands or a cocktail thereof can be
administered for prophylactic and/or therapeutic treatments. In n eutic
applications, an adequate amount to lish at least partial inhibition, suppression,
modulation, killing, or some other measurable ter, of a population of selected cells
is defined as a "therapeutically-effective dose". Amounts needed to achieve this dosage
will depend upon the severity of the disease and the general state of the patient's own
immune system, but generally range from 0.005 to 5.0 mg of selected peptide ligand per
kilogram of body weight, with doses of 0.05 to 2.0 mg/kg/dose being more commonly
used. For prophylactic applications, itions containing the present peptide ligands
or cocktails thereof may also be administered in similar or slightly lower dosages.
A composition containing a peptide ligand according to the present invention may be
utilised in prophylactic and therapeutic settings to aid in the alteration, inactivation, g
or removal of a select target cell population in a mammal. In addition, the selected
repertoires of polypeptides described herein may be used extracorporeally or in vitro
selectively to kill, deplete or otherwise ively remove a target cell tion from a
heterogeneous collection of cells. Blood from a mammal may be combined
extracorporeally with the selected peptide ligands y the red cells are killed
or otherwise removed from the blood for return to the mammal in accordance with
standard techniques.
(D) on of Polypeptides
The desired diversity is typically generated by varying the selected molecule at one or
more positions. The positions to be changed are selected, such that libraries are
constructed for each individual position in the loop sequences. Where appropriate, one
or more positions may be omitted from the ion procedure, for instance if it s
nt that those positions are not available for mutation without loss of activity.
The variation can then be achieved either by randomisation, during which the resident
amino acid is replaced by any amino acid or analogue thereof, natural or synthetic,
producing a very large number of variants or by replacing the resident amino acid with
one or more of a defined subset of amino acids, producing a more limited number of
variants.
Various methods have been reported for introducing such diversity. Methods for mutating
selected positions are also well known in the art and e the use of mismatched
oligonucleotides or degenerate oligonucleotides, with or without the use of PCR. For
example, several tic antibody libraries have been d by targeting mutations to
the antigen binding loops. The same techniques could be used in the context of the
present invention. For example, the H3 region of a human tetanus toxoid-binding Fab
has been randomised to create a range of new binding specificities (Barbas et al. (1992)
Proc. Natl. Acad. Sci. USA, 89: 4457). Random or semi-random H3 and L3 s have
been appended to germline V gene segments to e large libraries with mutated
framework regions nboom- & Winter (1992) R Mol. Biol., 227: 381; Barbas et al.
(1992) Proc. Natl. Acad. Sci. USA, 89: 4457; Nissim et al. (1994) EMBO J, 13: 692;
Griffiths et al. (1994) EMBO J, 13: 3245; De Kruif et al. (1995) J. Mol. Biol., 248: 97).
Such diversification has been extended to include some or all of the other antigen binding
loops (Crameri et al. (1996) Nature Med., 2: 100; Riechmann et al. (1995)
BiolTechnology, 13: 475; Morphosys, W097/08320, supra).
However, since the polypeptides used in the present invention are much smaller than
antibodies, the preferred method is to synthesise mutant ptides de novo.
Mutagenesis of structured polypeptides is described above, in connection with library
construction.
The invention is further described below with reference to the following examples.
Materials and Methods
Cloning of phage libraries
Phage libraries were generated according to Heinis et al., Nat Chem Biol 2009, 5 (7),
502-7). In Heinis et al, the genes encoding a semi-random peptide with the sequence
Xaa-Cys-(Xaa)3-Cys-(Xaa)3-, the linker Gly-Gly-Ser-Gly and the two disulfide-free
s D1 and D2 (Kather, et al., J Mol Biol 2005, 354 (3), 666-78) were cloned in the
correct orientation into the phage vector fd0D12 to obtain ‘library 3x3’. The genes
ng the peptide repertoire and the two gene 3 domains were step-wise created in
two consecutive PCR reactions. First, the genes of D1 and D2 were PCR amplified with
the two primer prepcr (5’-GGCGGTTCTGGCGCTGAAACTGTTGAAAGTAG-3’) and sfi2fo (5’-
GAAGCCATGGCCCCCGAGGCCCCGGACGGAGCATTGACAGG-3’; restriction site is
underlined) using the vector fdg3p0ss21 (Kather, et al., J Mol Biol 2005, 354 (3), 666-78)
as a template. Second, the DNA ng the random peptides was ed in a PCR
reaction using the primer sficx3ba: 5’-
TATGCGGCCCAGCCGGCCATGGCANNKTGTNNKNNKNNKTGCNNKNNKNNKNNKTGTNNKG
GGCGGTTCTGGCGCTG-3’ (restriction site is underlined), and sfi2fo. The ligation of 55
and 11 mg of SfiI-digested fd0D12 plasmid and PCR product yielded 5.6x108 colonies on
20x20 cm chloramphenicol (30 mg/ml) 2YT plates. Colonies were scraped off the
plates with 2YT media, supplemented with 15% glycerol and stored at -80°C.
Construction of the libraries described herein employed the same que to generate
the andom peptide Pro-Ala-Met-Ala-Cys-(Xaa)3-Cys-(Xaa)3-Cys for a 3x3 library for
example, and therefore replaced the sficx3ba primer sequence with: 5’-
TATGCGGCCCAGCCGGCCATGGCATGTNNKNNKNNKTGCNNKNNKNNKTGTGGCGGTTCTG
GCGCTG-3’. Libraries with other loop lengths were generated following the same
methodology.
Phage selections
Glycerol stocks of phage ies were diluted to OD600=0.1 in 500 ml
loramphenicol (30 mg/ml) cultures and phage were produced at 30°C over night
(15-16 hrs). Phage were purified and chemically modified as described in Heinis, et al.,
Nat Chem Biol 2009, 5 (7), 502-7 Biotinylated hPK (3 mg) (IHPKA, from human plasma,
Innovative Research, Novi, MI, USA) was incubated with 50 ml pre-washed magnetic
streptavidin beads (Dynal, M-280 from ogen, Paisley, UK) for 10 minutes at RT.
Beads were washed 3 times prior to blocking with 0.5 ml washing buffer (10 mM Tris-Cl,
pH 7.4, 150 mM NaCl, 10 mM MgCl2, 1mM CaCl2) containing 1% BSA and 0.1% Tween
for 30 minutes at RT with rotation. Chemically modified phage (typically 1010-1011 t.u.
dissolved in 2 ml washing buffer) were concomitantly blocked by addition of 1 ml g
buffer containing 3% BSA and 0.3% Tween 20. Blocked beads were then mixed with the
blocked chemically modified phage and incubated for 30 minutes on a ng wheel at
RT. Beads were washed 8 times with washing buffer containing 0.1% Tween 20 and
twice with washing buffer before incubation with 100 ml of 50 mM glycine, pH 2.2 for 5
minutes. Eluted phage were erred to 50 ml of 1 M Tris-Cl, pH 8 for neutralization,
incubated with 30 ml TG1 cells at OD600=0.4 for 90 minutes at 37 C and the cells were
plated on large 2YT/chloramphenicol plates. One or two additional rounds of panning
were performed using the same procedures. In the second round of selection,
neutravidin-coated magnetic beads were used to prevent the enrichment of streptavidinspecific
peptides. The neutravidin beads were prepared by reacting 0.8 mg neutravidin
(Pierce, Rockford, IL, USA) with 0.5 ml tosyl-activated magnetic beads , M-280
from Invitrogen, Paisley, UK) ing to the supplier’s instructions.
Cloning and expression of human, monkey and rat PK
The catalytic domain of human, monkey and rat PK was expressed in mammalian cells
as an inactive precursor having a pro-peptide connected N-terminally via a proTEV
ge site to the catalytic domain. The expression vector was cloned and the protein
expressed, activated and purified as described as follows. Synthetic genes coding for a
PK signal sequence, a polyhistidine tag, a proTEV cleavage site, mature catalytic domain
of PK and a stop codon were purchased from Geneart sburg, Germany)
(Supplementary materials). d DNA containing the synthetic genes for human,
monkey (Macaca mulatta) and rat PK was prepared and the gene transferred into the
pEXPR-IBA42 mammalian expression vector (IBA Biotechnology, Göttingen, y)
using the restriction enzyme pair XhoI and HindIII (Fermentas, s, Latvia) and T4
DNA ligase (Fermentas). The ligated plasmids were transformed into XL-1 blue
electrocompetent cells (Stratagene, Santa Clara, USA) and plated onto 2YT agar plates
containing ampicillin (10 μg/ml). DNA from the three sion vectors (termed mPK,
rPK and hPK) was produced and the correct sequences confirmed by DNA sequencing
(Macrogen, Seoul, South Korea).
The three orthologous plasma Kallikreins were expressed in mammalian cells as follows.
50 ml of suspension-adapted HEK-293 cells were grown in serum-free ExCell 293
medium (SAFC ences, St. Louis, MO) in the presence of 4 mM glutamine and the
histone deacetylase inhibitor valproic acid (3.75 mM) in an orbitally shaken 100 ml flask
at 180 rpm in an ISFW incubator (Kühner AG, Birsfelden, Switzerland) at 37 °C in the
presence of 5% CO2. The nic kidney 93) cells at high cell density (20 x 106
cells/ml) (Backliwal, et al/. Biotechnol Bioeng 2008, 99 (3), 721-7) were transfected with
the three plasmids (300mg/ml) using linear polyethylenimine (PEI, Polysciences,
Eppenheim, Germany). At the end of the 7-day production phase, cells were harvested
by centrifugation at 2'500 rpm for 15 min at 4°C. Any additional cell debris was removed
from the medium by filtration through 0.45 μm PES nes (Filter-top 250 ml low
protein binding TPP). The polyhistidine-tagged protein was purified by Ni-affinity
chromatography using Ni-NTA resin, washing buffer (500mM NaCl, 25mM Na2HPO4,
pH7,4) and n buffer (500 mM NaCl, 25 mM Na2HPO4, pH 7,4, 500 mM imidazole).
The n was partially activated with (50 units) proTEV (Promega, Madison, Wisconsin,
USA) and additionally purified by Ni-affinity tography and gel filtration (PD10
column, 150 mM NaCl, 0,5 mM EDTA, 50 mM HEPES, pH 7).
Development of polypeptides with improved g activity
isation of individual positions
Library construction: In order to map the amino-acids in the Kallikrein binding bicyclic
peptides a set of small ies was constructed. For a bicycle comprised of 2 loops of 5
residues, 10 separate libraries were generated each with randomisation at a particular
codon in the peptide sequence. Oligonucleotides were designed for each library in order
to mutate the phage genome DNA by site-directed mutagenesis. The mutagenesis
incorporated randomisation of the codon of interest (change to NNS), and removal of a
unique ApaL1 restriction site from the template genome ce. The mutagenesis
product was purified using QIAgen QIAquick PCR purification kit with elution into
ultrapure water. Each library was used to separately transform TG1 E coli by
electroporation with a BioRad Micropulser machine (Ec1 program) and 1mm BioRad
cuvette. After 1 hour ry at 37C in 1ml SOC media, the library transformants were
grown overnight in 25ml 2TY broth containing antibiotic to selectively grow library
transformants only. The bacteria were harvested by centrifugation and the library phage
DNA was purified from the E coli using a QIAgen d Plus Midi kit and eluted in
distilled water. The purified DNA was digested with ApaL1 for 2 hours in New England
Biolabs buffer 4 to remove the parent al. After digestion, the DNA was repurified
using QIAgen PCR purification kit (as above) and used to transform TG1 (electroporation;
as described above). ing the 1 hour recovery in SOC, transformants were plated
on LB-agar plates containing selective antibiotic and colonies allowed to grow overnight
at 37C.
Assay of binding of individual clones: Library ormant colonies were picked at
random and grown as individual cultures in 2TY broth containing selective antibiotic. The
picked colonies were DNA-sequenced using a QIAgen PyroMark Q96 DNA sequencer to
reveal the amino-acid substitution present in each clone. Where isolated, a clone of each
unique substitution was assayed for human plasma Kallikrein binding as follows. The
phage-containing supernatant was harvested from the culture and phage were cyclised
with tris bromomethyl benzene(TBMB) based on the methods of Heinis et al (Nature
Chemical y vol. 5 pp 502-507 (2009)). The purified phage from this process were
assayed for binding to biotinylated human plasma Kallikrein using a homogeneous platebased
binding assay; assay read-out measured on a BMG h Pherastar FS plate
reader. The quantitative binding data from cate assay s was averaged (mean)
and expressed as signal:background (where ound was a sample assayed with no
target material). The signal:background was expressed as a % of the parallel parent
. Error bars denote standard deviation of the mean. Assays shown are
representative of at least 2 ndent experiments. The assay data was correlated with
the peptide sequences. Substitutions marked in grey were not tested (a clone was not
isolated from the random library sampling). A sample of a non-binding (arbitrary) bicycle
was assayed in parallel to illustrate the assay baseline.
Randomisation of peptide domains
Library construction: Small phage libraries were generated according to the methods of
Heinis et al as described in ng of phage ies’ above. The sficx3ba primer was
modified such that the bicycle-encoding portion was based on a parent 5x5 bicycle (5x5:
two 5-residue loops) DNA sequence with only 4-6 codons randomized to NNS. The
randomized codons were those encoding the peptide domain/motif of interest.
Assay of binding of individual clones: Library transformant colonies, or selection output
colonies, were picked and grown as individual cultures in 2TY broth containing selective
otic. The picked colonies were DNA-sequenced using a QIAgen PyroMark Q96 DNA
cer to reveal the amino-acid substitution present in each clone, and were d
for human plasma Kallikrein binding as follows. The phage-containing supernatant was
ted from the culture and phage were cyclised with tris bromomethyl
benzene(TBMB) based on the methods of Heinis et al (Nature Chemical y vol. 5
pp 502-507 (2009)). The purified phage from this process were assayed for binding to
biotinylated human plasma Kallikrein using a homogeneous plate-based binding assay;
assay read-out measured on a BMG Labtech Pherastar FS plate reader. The quantitative
g data from duplicate assay samples was averaged (mean) and expressed as
:background. Assay data shown is representative of at least 2 independent
experiments. The assay data was correlated with the peptide sequences.
Synthesis and purification of bicyclic es
Peptide sequences are shown in Tables 1 and 2. Peptide synthesis was based on Fmoc
chemistry, using a Symphony peptide siser manufactured by Peptide Instruments.
Standard Fmoc-amino acids were ed (Sigma, Merck), with the following side chain
protecting groups: Arg(Pbf); Asn(Trt); Asp(OtBu); Cys(Trt); GIu(OtBu); Gln(Trt); His(Trt);
Lys(Boc); Ser(tBu); u); c), Tyr(tBu) ). The coupling reagent was
HCTU (Pepceuticals), diisopropylethylamine (DIPEA, Sigma) was employed as a base,
and deprotection was achieved with 20% piperidine in DMF (AGTC). Syntheses were
performed at 100 umole scale using 0.37 mmole/gr Fmoc-Rink amide AM resin (AGTC),
Fmoc-amino acids were utilised at a four-fold excess, and base was at a four-fold excess
with respect to the amino acids. Amino acids were dissolved at 0.2 M in DMF, HCTU at
0.4 M in DMF, and DIPEA at 1.6 M in N-methylpyrrolidone (Alfa Aesar). Coupling times
were lly 30 s, and deprotection times 2 x 2.5 minutes. Fmoc-N-
methylglycine (Fmoc-Sar-OH, Merck) was coupled for 1 hr, and deprotection and
ng times for the following residue were 20 min and 1 hr, respectively. After
synthesis, the resin was washed with dichloromethane, and dried. Cleavage of side-chain
protecting groups and from the support was ed using 10 mL of 95:2.5:2.5:2.5
v/v/v/w TFA/H2O/iPr3SiH/dithiothreitol for 3 hours. Following cleavage, the spent resin
was removed by filtration, and the filtrate was added to 35 mL of diethylether that had
been cooled at -80 deg C. Peptide pellet was centrifuged, the etheric supernatant
discarded, and the peptide pellet washed with cold ether two more times. Peptides were
then resolubilised in 5-10 mL acetonitrile-water and lyophilised. A small sample was
d for analysis of purity of the crude product by mass spectrometry (MALDI-TOF,
Voyager DE from Applied Biosystems). Following lyophilisation, peptide powders were
taken up in 10 mL 6 M guanidinium hydrochloride in H2O, supplemented with 0.5 mL of 1
M dithiothreitrol, and loaded onto a C8 Luna preparative HPLC column (Phenomenex).
Solvents (H2O, acetonitrile) were ied with 0.1 % heptafluorobutyric acid. The
gradient ranged from 30-70 % acetonitrile in 15 minutes, at a flowrate of 15/20 mL /min,
using a Gilson preparative HPLC system. Fractions containing pure linear peptide
material (as identified by MALDI) were combined, and modified with
trisbromomethylbenzene (TBMB, . For this, linear e was diluted with H2O up
to ~35 mL, ~500 uL of 100 mM TBMB in acetonitrile was added, and the reaction was
initiated with 5 mL of 1 M NH4HCO3 in H2O (pH 8). The reaction was d to proceed
for ~30 -60 min at RT, and lyophilised once the reaction had completed (judged by
MALDI). Following lyophilisation, the modified peptide was purified as above, while
replacing the Luna C8 with a Gemini C18 column (Phenomenex), and changing the acid
to 0.1% trifluoroacetic acid. Pure fractions containing the correct TMB-modified material
were pooled, lyophilised and kept at -20 deg C for storage.
Non-natural amino acids were ed from the sources set forth in Table 7.
Bulky or hindered amino acids (NMe-Ser, NMe-Trp, NorHar, 4PhenylPro, Agb, Agp, NMe-
Arg, Pen, Tic, Aib, Hyp, NMe-Ala, NMe-Cys, Al, A, Dpg, 1NAl, 2NAl, Aze,
4BenzylPro, Ind) were usually coupled for 1 hours (20 min deprotection), and 6 hrs for the
residue that followed (20 min ection). HCTU was used as a coupling reagent as
before. Scale was usually at 50 umole.
Enzyme assays
Functional enzyme assays were conducted in 10mM Tris HCl, 150mM NaCl, 10mM
MgCl2, 1mM CaCl2 and 1mg/mL BSA (all Sigma UK) pH7.4 at 25°C in solid black 96 well
. Briefly 26.5pM human plasma rein (purchased from Stratech, UK) or 500pM
rat plasma Kallikrein (expressed and purified in house) were incubated in the absence or
presence of increasing concentrations of test peptide for 15 minutes before addition of
the fluorogenic ate rg-AMC (Enzo Lifesciences UK) to a final assay
concentration of 100µM in 4% DMSO. Release of AMC was measured using a Pherastar
FS (BMG Labtech), excitation 360nm, emission 460nm. The rate of the linear phase of
the reaction, typically 5 to 45 minutes, was calculated in MARS data analysis software
(BMG labtech). The rate was then used to calculate the IC50 and Ki in Prism (GraphPad).
A four parameter inhibition non-linear regression equation was used to calculate the
IC50. The One site – fit Ki on used to calculate the Ki, constraining the Ki to the Km
for the substrate which is 150µM. All Ki/IC50 values are the mean of at least two
independent experiments, and at least three for peptides with Ki values lower than 1 nM.
Peptides were dissolved as the TFA-salts in their powder form, and stock solutions were
usually prepared in water. All solutions were centrifuged and filtered (20 mm syringe
filters) prior absorption measurement at 280 nm. Extinction coefficients were calculated
based on the Trp/Tyr content of the peptide, and that of TMB (the TMB core, when
contained in a peptide, has an e of ~300 M-1cm-1). For peptides containing non-natural
amino acids with suspected chromophoric properties (i.e. NorHar, 4PhenylPro, 3Pal,
4Pal, Tic, he, 4,4-BPAl, 3,3-DPA, 1NAl, 2NAl, 4BenzylPro, Ind) concentrations
were ined by weighing the powder and dissolving the peptide in a defined quantity
of water. These were ed independently, twice, for peptides with a Ki to rein at
1 nM or less.
Plasma ity profiling
Three methods were employed to assess the stability of es (peptides conjugated to
molecular scaffolds) in plasma.
Method 1:
A rapid plasma stability profiling assay was developed that employed mass
spectrometric detection (MALDI-TOF, Voyager DE, Applied Biosystems) of the parent
mass, until the time when the parent peptide mass was no longer observable.
Specifically, 200 uM of peptide was incubated in the ce of 35% rat or human
plasma (Sera labs, using citrate as agulant) at 37 deg C, which was supplemented
with 1 x PBS (derived from a 10 xPBS Stock, Sigma). At various time points (i.e. t = 0, 3,
24 hrs, henceafter daily up to 10 days), 2 uL of sample was added to 18 uL of 30 mM
ammonium bicarbonate in a 1:1 mixture of acetonitrile:H2O. Samples were frozen at -80
deg C until the time of analysis. For mass spectrometric is that determines the
approximate detection window of the peptide, the acetonitrile:H2O-diluted sample of a
given time point was spotted directly (0.7 uL) onto the MALDI plate. Matrix (alphacyanocinnamic
acid, Sigma, ed as a ted solution in 1:1 itrile:water
containing 0.1% trifluoroacetic acid) was layered over the sample (1 uL). At a similar laser
intensity setting on the MALDI TOF, the time could then be determined until parent
peptide was no longer detectable. It should be noted that this is a qualitative assay
serves to detect relative changes in plasma stability.
Method 2:
To obtain ity data more rapidly, peptides were also ed in 95% plasma.
Here, PBS was omitted, and a 1 mM peptide stock (in DMSO) was directly diluted into
plasma (i.e. 2.5 uL stock into 47.5 uL plasma), giving a final concentration of 50 uM. 5 uL
samples were taken at appropriate time points and frozen at -80 deg C. For analysis, the
samples were defrosted, mixed with 15 uL of 1:1 acetonitrile:methanol, and centrifuged at
13k for 5 min. 5 uL of the peptide-containing supernatant was aspirated and mixed with
mM ammonium bicarbonate in a 1:1 mixture of acetonitrile:H2O. 1 uL of this was then
spotted on the MALDI plate and analysed as described above. As above, it should be
noted that this is a qualitative assay serves to detect relative changes in plasma ity.
Method 3:
To obtain plasma stability quantitatively, peptide stock solutions (1 mM in DMSO)
were shipped to Biofocus, UK, who performed the analysis. Peptides were diluted to 100
uM with water, and diluted 1:20 in plasma (5 uM final concentration, with the plasma at
95%), sampled as appropriate, precipitated as above, and quantified using a Waters
Xevo TQ-MS.
Example 1: Identification of preferred residues for binding activity
From the examples of 5x5 peptides shown in Table 4 it is possible to identify amino acids
that are conserved between peptides with binding activity. To determine which residues
were preferred for binding activity, representatives from two of the identified families of
es were studied further. These were peptides 06-34, which comprises a
CXWPARC motif in the first loop of the bicycle, and peptide 06-56, which comprises a
CGGxxNCR motif across both loops of the bicycle. For each peptide sequence, a set of
phage libraries was created in which 9 of the loop es were kept constant and the
other residue was randomised so that any acid could be expressed in the library at
that position. (See ‘Randomisation of individual positions – Library construction’ in
Methods above.) For each library a set of 20 randomly selected phage clones were
screened for binding to human Kallikrein in a phage binding assay to identify the critical
residues for target binding. (See ‘Randomisation of individual positions – Assay of binding
of individual clones’ in Methods above.) The data from this experiment are shown in
Figures 4 - 6.
For peptide 06-34 (Figure 4), it is clear that Arg1 of the e can be replaced with a
variety of different acids and binding to human plasma rein is retained or
enhanced. By contrast, replacement of residues 2, 3, 4, 5 (Trp2, Pro3, Ala4, Arg5) by
most amino acids greatly reduced the signal seen in an assay that was set up with a
stringent cut-off for high affinity s. Val6 can be replaced by many different cids
and binding activity is retained or enhanced. Replacement of other residues in the
second loop indicated that only Leu10 could be replaced by a variety of different aminoacids
whilst retaining ty. Positions 7, 8, and 9 have limited capacity for substitution
and no substitutions were identified that enhanced binding.
For peptide 06-56 (Figures 5 and 6) it is clear that glycines at position 1 and 2 are the
greatly preferred residues for g to plasma Kallikrein as are arginine, tryptophan and
threonine at positions 6, 8, and 9. Glutamine at position 4 and ine at position 10
can be replaced by a variety of residues whilst retaining good g activity. The three
ing residues – proline at position 1, asparagine at position 5 and threonine at
on 7 have limited capacity for substitution.
Analysis of amino-acid replacements
From the preceding analysis it is apparent that for 06-34, position one and position six
can be replaced by a variety of amino-acids and still retain binding ty equal or
greater than that of the parent peptide. To evaluate whether these observations would
hold with isolated synthetic peptides, a set of peptides was designed according to the
findings in Figure 4, where Arg1 was replaced by a serine, and where Val6 was
tuted by either threonine, methionine or leucine. Peptides employing the various
combinations of these tutions were also synthesised. These substitutions produced
a greater binding signal in the assay (Table 5).
All of the variant synthetic peptides had approximately equivalent or ed activity
against human plasma Kallikrein in enzyme inhibition assays compared to the 06-34
parent peptide, indicating that this type of analysis could be used to fine-tune target
binding affinities, and suggesting a route to identifying lead peptide candidates of very
high potencies.
The peptides were also tested against rat plasma Kallikrein in isolated enzyme assays.
Substitution of Arg1 to Ser1 had a al impact on activity against rat Kallikrein,
whereas substitutions of Val6 to threonine, methionine or leucine generated peptides with
markedly increased potency against rat plasma Kallikrein. Activity to human Kallikrein
was fully retained. Thus, by ining positions amenable to tutions, peptides
with ble properties, such as target orthologue cross-reactivity, can be identified.
To demonstrate the possibility of replacing these two positions with non-natural amino
acids so as to have the capacity to introduce functionalities or properties that are not
present in the parent peptide, Arg1 and Val6 in 0603 were replaced with either
alanine or N-methylglycine (sarcosine), or with N-methyl serine on position 1, and
evaluated for binding. Remarkably, as shown in Table 6, positions 1/6 are amenable to
removal of the side chain altogether, as the R1A/V6A (0603 ) peptides retained
full potency compared to the parent. Replacement of residues 1,6 with N-methylglycine
(0603 NMeGly1,6) caused a reduction in y, however the binding affinity
remained in the low nanomolar range. uction of an N-methylserine at position 1
causes a ten-fold loss in y, but binding remains in the picomolar range. Thus,
certain positions in the bicycle can be identified that allow changes in the peptide
backbone structure or side chains, which could allow for rate enhancement of
protease stability, ed solubility, reduced aggregation potential, and introduction of
orthologous functional .
Example 2: Detailed analysis of WPAR domain.
The WPAR motif identified from Example 1 was analysed in the context of the 0603
peptide, in order to identify alternatives or improvements to the WPAR motif. A library
was ucted where positions 1, 6, 7, 8, 9 &10 of 0603 were fixed and positions 2,
3, 4 & 5 were ised (see ‘Randomisation of peptide domains – Library construction’
in Methods above). Selections against human plasma Kallikrein were performed at a
y of encies (see Phage selections’ in Methods above). All output sequences
were fied and ed for target binding (see ‘Randomisation of peptide domains –
Assay of binding of individual ’ in Methods above). Table 17 lists each unique
sequence, its relative abundance in the selection output (frequency), and a rank number
according to target binding strength.
Table 17 shows that WPAR motif confers the best binding to human plasma Kallikrein,
although other Kallikrein binding sequences are retrieved from selections in high
abundance. These include, but are not cted to: WPSR, WPAR, WSAR, WPFR,
WPYR, FPFR, & FPFR. The most effective and abundant motifs at positions 2, 3, 4 & 5
can be summarised as: W/ K/
F P x R
Table 18(A) shows that WPAR & WPSR were most abundant in the more stringent
selection outputs; FPFR & FPYR were abundant in the lower stringency selection
outputs. This would te that WPAR-like ces are stronger binders than FPFR-
like sequences. Analysis of each motif (within the 0603 context) in the target binding
assay (Table 18(B)), reveals that WPAR at positions 2, 3, 4 & 5 of the 0603 sequence
is the optimal sequence for Kallikrein binding.
Example 3: Optimisation of sequence outside WPAR
The WPAR motif and its variants have been studied within the context of peptide 06
03. Figure 1 demonstrates that some positions outside of the WPAR motif can maintain
Kallikrein binding when substituted for other residues. In order to study the non-WPAR
determinants of Kallikrein binding, a phage library was generated with a fixed-WPAR
sequence and all other positions randomised (CxWPARCxxxxxC) as described in
misation of peptide domains – Library construction’ in Methods above.
80 random library members were isolated directly from the library pool (no selection) and
assayed for binding to Kallikrein at both high and low stringency (see ‘Randomisation of
peptide domains – Assay of binding of individual ’ in Methods above). These library
s, which contain random sequences outside the WPAR, showed little or no
binding to human plasma Kallikrein (data not shown), indicating that the presence of a
WPAR motif alone is not sufficient to retain measureable rein binding: the rest of the
bicycle sequence must also contribute or influence the interaction.
Selections against human plasma Kallikrein were performed with this library in order to
study the non-WPAR determinants of Kallikrein binding, and to isolate the optimal WPAR-
ning peptide sequence. Over 150 selection output sequences were isolated and
screened for binding to human plasma Kallikrein (as described in Methods above). The
sequences were ranked in order of rein binding and the top 50 sequences were
aligned in Table 19. Table 19 shows that the residue at position 1 does not affect
Kallikrein binding, but a strong consensus for Histidine is seen at position 7 (which
ts findings in Example 1 above). The peptide 03 – derived from the work in
Example 1 – is one of the best ces. The composition of the second loop shows
clear trends which confer strong Kallikrein binding when with a WPAR motif.
The best ontaining binders to human plasma Kallikrein have the trend:
C X W P A R C T/ Q/
L H T D L C
H7, D9 and L10 are heavily conserved in WPAR-containing Kallikrein binding ces.
Two motifs in within the second bicycle loop (positions 6-10) were identified:
1. C X W P A R C T H Q/ T D L C (positions 6, 7 &10: “THxxL”)
2. C X W P A R C T/ Q/
L H T D L C (positions 7, 8, & 10: “xHxDL”)
Over 120 identified human plasma Kallikrein s (selection output sequences) were
grouped 2 different ways, according to their derivation from motifs “THxxL” or “xHxDL”.
For all groups, the average Kallikrein binding assay signal for output sequences was
noted as a measure of Kallikrein binding for a given group (Table 20).
The rein binding assay data shown in Table 20 demonstrates that ’ and
‘xHxDL’ motifs result in the best Kallikrein binding when in a bicyclic peptide with a WPAR
motif. The combination of the 2 motifs, ‘THxDL’, gives the highest binding to human
plasma Kallikrein and includes the ‘THQDL’ second loop sequence of the 0603
peptide.
Example 4: Systematic analysis of plasma stability.
For a Kallikrein-inhibiting bicycle, it is pertinent to obtain an adequate se stability
profile, such that it has a low protease-driven clearance in plasma or other relevant
environments. In a rapid comparative plasma stability assay (methods section, method1)
that observed the progressive disappearance of parent peptide in rat plasma, it was
found that the N-terminal alanine (which is present at the time of selections and was
originally included in tic peptides of lead sequences) is rapidly removed across all
bicycle sequences tested by both rat and human plasma. This degradation was avoided
by synthesising a lead candidate lacking both N- and C-terminal alanines. To remove
potential recognition points for amino- and carboxypeptidases, the free amino-terminus
that now resides on Cys 1 of the lead candidate is capped with acetic anhydride during
peptide synthesis, leading to a molecule that is N-terminally acetylated. In an equal
measure, the C-terminal cysteine is synthesised as the amide so as to remove a potential
recognition point for carboxypeptidasese. Thus, ic lead candidates have the
following generic sequence: Ac-C1AA1AA2AAnC2AAn+1AAn+2AAn+3C3(TMB)-NH2, where
"Ac" refers to N-terminal ation, "-NH2" refers to C-terminal amidation, where "C1,
C2, C3" refers to the first, second and third cysteine in the ce, where "AA1" to "AAn"
refers to the position of the amino acid (whose nature “AA” is defined by the selections
described above), and where "(TMB)" indicates that the e sequence has been
cyclised with TBMB or any other suitable reactive scaffold.
Due to the high affinity of Ac34-18(TMB)-NH2 to both human (Ki = 0.17 nM) and rat
Kallikrein (IC50 = 1.7 nM), we chose this Bicycle for lead development. Using the same
rapid plasma stability profiling assay described above, Ac34-18(TMB)-NH2 had an
observability window of about 2 days ds section, method 1), which s to a rat
plasma halflife of ~ 2 hrs (as determined quantitatively by LC/MS, see below, table 23 ,
method 3).
In an effort to identify the lytic recognition site(s) in Ac34-18(TMB)-NH2, the
peptide was sampled in 35% rat plasma over time (method 1), and each sample was
analysed for the progressive appearance of peptide fragments using MALDI-TOF mass
spectrometry. The parent mass of Ac34-18(TMB)-NH2 is 1687 Da. Over time (Figure
7), fragments appear of the masses 1548.6 (M1), 1194.5 (M2), and 1107.2 (M3). From
the sequence of 34-18(TMB)-NH2 (Ac-C1S1W2P3A4R5C2L6H7Q8D9L10C3-NH2), it
can be calculated that the peak of M1 ponds to Ac34-18(TMB)-NH2 lacking
Arg5 (-R5). This appears to be the initial proteolytic event, which is followed by removal of
the o acid segment WPAR in Ac34-18(TMB)-NH2 (M2, -WPAR), and finally the
entire first loop of Ac34-18(TMB)-NH2 is d (M3, -SWPAR) (Figure 8). From this
data, it is evident that Arg5 of Ac34-18(TMB)-NH2 is the main rat plasma protease
recognition site that is sible the degradation of the Bicycle.
e substitutions and scrambling of first loop:
Having identified Arg5 in constituting the recognition site for rat plasma proteases, a
campaign of chemical synthesis of Ac34-18(TMB)-NH2 derivatives was undertaken
with the aim of identifying candidates with higher plasma proteolytic stability. Crucially,
such modifications should not affect the potency against human or rat Kallikrein. An initial
exploration regarding the role of the WPAR sequence/pharmacophore (Figure 9, 10) was
performed by replacing W2P3 with A2A3 or A2Q3 and by scrambling parts or the entire first
loop of the bicycle. Table 8 below shows the ces and the respective ties
against Kallikrein.
From these data it is clear that concomitant removal of W2P3 ically reduces g
to Kallikrein by a factor of 0, effectively rendering the molecule cologically
inert. The importance of the correct sequence of the amino acids is underlined by the four
scrambled peptides (Scram2-4), as all of them display a substantial reduction in ty
towards Kallikrein (Figure 10). Curiously, all peptides have a roughly identical rat plasma
ity profile en 1 to 2 days, method 1), ting that plasma protease
recognition relies on the presence of the arginine (Figure 7), and not on its position within
the sequence.
Next, five derivatives of Ac34-18(TMB)-NH2 were generated where W2, P3, A4, R5,
and C2 were replaced with their respective D-enantiomeric counterparts (Table 9).
From the data it is clear that D-amino acid replacement of A4, R5, and C2 increase peptide
stability towards plasma proteases. As Arg5 excision by rat plasma proteases appears to
be the first event in peptide degradation, the initial hydrolysis of peptide bonds will occur
on the N- and/or C-terminal side of Arg5. It is plausible that replacing the amino acids to
either side of Arg5 with their D-enantiomers blocks adjacent peptide bond hydrolysis
through steric hindrance. Indeed, this is an effect that has been observed previously
(Tugyi et al (2005) PNAS, 102(2), 413–418).
The detrimental effect of D-amino acid substitution on affinities to rein is striking in
all cases; losses in potencies range from 300- (D-Arg5) to 45000-fold (D-Trp2). This
underlines the importance of the correct three-dimensional y of these sidechains to
the Kallikrein bicycle binding pocket. Equally striking is the effect of D-Ala4: here,
changing the orientation of a single methyl group (being the Ala side chain) reduces the
affinity 7000-fold.
N-methylations:
Next, residues in the first loop were systematically replaced with their yl
counterparts. N-methylation serves as a straightforward protection of the peptide bond
itself; however, due to the absence of the amide hydrogen, addition of steric bulk (the
methyl group) and changes in preferred torsional angles, losses in potencies are
expected.
Table 10 summarises the data.
N-methylation of amino acids in loop 1 displays an altogether less drastic detrimental
effect on potency. In ular, N-methylation of Arg5 still yields a single digit nanomolar
binder (20-fold reduction in affinity compared to wildtype peptide), and its rat plasma
stability exceeds the assay time (fragmentation of the peptide in the MS was not
observable), making this an tive ed lead candidate. As with the o acid
substitutions, N-methylation of residues adjacent to Arg5 imparts enhanced stability to the
peptide, presumably through steric interference affecting protease-catalysed ysis of
peptide bonds N and/or C-terminal to Arg5. Of note, Ser1 can be N-methylated without a
icant loss in potency, ting that the integrity of the peptide backbone in this
position is not essential for binding.
Arginine substitutions:
Given the importance of Arg5 in recognition by rat plasma proteases, a set of arginine
analogues were tested in the 34-18(TMB)-NH2 lead. The chemical structures are
shown in Figure 11, and the potency versus stability data is shown in Table 11.
ngly, all arginine analogues increase the stability of the peptide beyond the assay
window time, confirming the importance of the integrity of Arg5 in plasma protease
recognition. Increasing (HomoArg) or decreasing the length of the side chain (Agb, Agp)
both decrease affinity, however the HomoArg analogue still yields a very good binder (Ki
= 2.1 nM), with enhanced stability. Lengthening the amino acid backbone by one
methylene group in Arg5 (a so-called beta-amino acid) while retaining the same side
chain (b-homoArg5) also yields a binder with ed stability, r at the price of
a more significant reduction in affinity (Ki = 8.2 nM). Replacing the aliphatic part of the
Arg side chain with a phenyl ring yields a nce stabilised, bulkier and rigidified
guanidyl-containing side chain (4GuanPhe). Of all the Arg analogues tested, 4GuanPhe
had the greatest affinity (2-fold reduction compared to wildtype), at an enhanced plasma
stability. Interestingly, the guanidylphenyl group is urally close to the known small
molecule Kallikrein inhibitor benzamidine (Stürzebecher et al (1994), Novel plasma
Kallikrein inhibitors of the benzamidine type. Braz J Med Biol Res. 27(8):1929-34; Tang et
al (2005), Expression, crystallization, and three-dimensional structure of the tic
domain of human plasma Kallikrein. J.Biol.Chem. 280: 41077-89). Furthermore,
derivatised Phenylguanidines have been ed as selective inhibitors of another
serine protease, uPA (Sperl et al, (4-aminomethyl)phenylguanidine derivatives as
nonpeptidic highly selective inhibitors of human urokinase (2000) Proc Natl Acad Sci U S
A. 97(10):5113-8.). Thus, Ac34-18(TMB)-NH2 containing 4GuanPhe5 can be viewed
as a small molecule inhibitor, whose selectivity is imparted by the nding Bicyclic
peptide. This can comprise a principle for other e-based inhibitors, where a known
small molecule tor of low selectivity is “grafted” onto a Bicycle in the correct position,
leading to a molecule of superior potency and selectivity.
Modification of the Arg guanidyl-group itself, either by methylation (SDMA, NDMA),
removal of the positive charge (Cit, where the guanidyl group is replaced by the isosteric
but uncharged urea group) or deletion of the Arg altogether (D Arg) has strongly
detrimental s on Kallikrein binding potency. Thus, the integrity and presence of the
guanidyl group is crucial, while the nature of the sidechain connecting to the guanidyl
group or backbone at Arg5 is not. Of note, Arg5 may also be replaced by lysine, however
again at reduced affinities (see WPAK peptide).
In summary, data this far indicates that Ac34-18(TMB)-NH2 employing either
HomoArg, NMeArg or 4GuanPhe as ne replacements could constitute plasma
stability enhanced candidates with high affinities.
Example 5: Improving the potency of a lead candidate through tural
modifications and combination with plasma-stability enhancing modifications.
Improving the potency of a given bicyclic ate can be feasibly ed through
several isms. These have been partially addressed in Example 4, and can be
ten as follows:
1. Incorporating hydrophobic moieties that exploit the hydrophobic effect and lead to
lower off rates, such that higher affinities are achieved.
2. Incorporating charged groups that t long-range ionic interactions, leading to
faster on rates and to higher affinities (see for example Schreiber et al, Rapid,
electrostatically assisted association of proteins (1996), Nature Struct. Biol. 3,
427-31)
3. Incorporating additional constraint into the peptide, by i.e.
- aining side chains of amino acids correctly such that loss in
entropy is minimal upon target g
- Constraining the torsional angles of the backbone such that loss in
entropy is l upon target binding
- Introducing additional cyclisations in the molecule for identical reasons.
(for reviews see ucci et al, Curr. Pharmaceutical Design, (2010), 16, 3185-203, and
Nestor et al, Curr. Medicinal Chem (2009), 16, 4399-418).
Tryptophan and hydrophobic analogue substitutions:
Initially, a range of hydrophobic amino acids were substituted into the Trp2 site to fy
candidates that could replace the oxidation sensitive tryptophan, and to identify
candidates that could increase potencies (addressing the first point . The side
chains of these amino acids are shown in Figure 12, and affinity data is summarised in
Table 12 below.
As expected, none of the modifications increase plasma stability. 2-Naphtylalanine is
most closely related to Trp2 and displays a potency slightly weaker than wildtype, making
this a good, oxidation-resistant replacement for Trp2. stingly, 3,3-DPA2 has a
structure that is very dissimilar to Trp, yet the corresponding peptide retains high
potency. This may indicate that the Trp contacting pocket on Kallikrein could be exploited
for higher affinity binding by identifying a correctly ed hydrophobic entity.
Proline Analogues:
Next, we were interested in determining the role of Pro3 in the WPAR cophore in
Ac34-18(TMB)-NH2. 4-hydroxy- or 4-fluoro-trans (L)-proline (HyP3, 4FluoPro3) were
chosen for their known property in inducing additional rigidity and helicity on the peptide
backbone (Figure 15, Table 13). Additionally, the presence of the yl on HyP probes
the solvent accessibility of the proline side chain. Ki's of the respective derivatives were
almost identical to that of wildtype, indicating that any effects on the peptide backbone
are negligible, but also demonstrating that the side chain is accessible. To elaborate this
r, two additional derivatives of 34-18(TMB)-NH2 were tested, which
contained bulky extension on the g-carbon of the Pro3 ain (4Phenyl-Pro, 4Benzyl-
Pro). The former displayed a striking preservation of potency, while the latter was
severely impacted, demonstrating that the Pro side chain is accessible, but limited to
ct modifications only. Despite the steric bulk in these modifications, plasma stability
was identical to that of wildtype. Thus, these modifications do not improve ivity
against other proteases.
To probe the effect of proline ring size on binding, the highly constrained 4-membered
Pro analogue ine carboxylic acid (Aze), and the more flexible 6-membered ring
(pipecolic acid, Pip) were substituted for Pro3. Ac34-18(TMB)-NH2 Aze3 binds
Kallikrein with the highest affinity of all derivatives so far, surpassing that of wildtype by a
factor of 3 (Figure 14). There appears to be an inverse relationship between ring size and
Ki, which would t that conformational constraint at position 3 of Ac34-
18(TMB)-NH2 is key to a tightly binding molecule.
The flexibility of the proline side chain in tolerating large bulky groups is underlined by the
cyclic proline analogues Tic, NorHar and Ind (Figure 13). Particularly for the latter two
cases, affinities are still well in the one digit nanomolar range.
Finally, we sought to probe the requirement for the ring structure at Pro3 altogether. To
this end, we chose aminoisobutyric acid (Aib, Figure 13, Table 13), which, due to its
double methyl substitution at the alpha , has a strong structural effect on the
neighbouring amino acids in inducing a or 310 helicity (Toniolo et al , Biopolymers
33, 1061-72; Karle et al (1990), Biochemistry 29, 6747-56). Remarkably, this nonnatural
non-cyclic amino acid is well tolerated in place of Pro3, at a Ki of 1.2 nM. Thus,
the role of Pro3 in the WPAR pharmacophore is to introduce a constraint onto the peptide
backbone. This constraint can be ed by employing a proline analogue with
reduced ring size (see Aze3). sely, the proline ring can be replaced vely
efficiently with non-cyclic but structure-inducing amino acids, such as Aib.
Miscellaneous Analogues:
In table 10, it was shown that Ser1 in loop 1 of Ac34-18(TMB)-NH2 could be N-
methylated with very minor impact on potency (0.5 versus 0.17 nM Ki in WT). We sought
to determine whether this location tolerated a large double substitution on Ca at position
1. To this end, Ser1 was replaced with Dpg pylglycine) (Figure 15). The affinity of
this peptide to Kallikrein is at 1.1 nM, indicating that on 1 is very flexible in
accommodating virtually any bulky residue. Thus, this position in loop 1 could be
exploited for deliberate inclusion of desirable chemical functionalities or groups, including
lising amino acids, radio labels, dye labels, linkers, conjugation sites et cetera.
Several alanine analogues were also tested at position 4. As already seen with the N-
methyl and D-alanines (Table 2, 3), Ala4 is highly sensitive to the steric orientation at Ca,
or to cation on the backbone itself. Two more derivatives of this class underline this,
as elongation of the peptide backbone at Ala4 4) ically reduces affinity (~20
mM). As expected from D-Ala4, Aib4 s ty to almost the same extent (289 nM,
Figure 15 and Table 14). Remarkably, extension of the Ala sidechain by one ene
(Aba4) appears to enhance the ty to Kallikrein.
Finally, the central cysteine (Cys2) was replaced with a bulkier and more constrained
analogue, penicillamine (Pen, Figure 15) in the hope of increasing proteolytic stability due
to reduced spatial access to the ourging Arg5 protease recognition point. Indeed,
rat plasma ity was slightly enhanced, however potency d significantly,
underlining the importance of the full integrity of this structural scaffold-connecting
residue.
Combination of plasma stability ing and potency enhancing tural amino
acids into a single Bicycle lead
Non-natural substitutions in Ac34-18(TMB)-NH2 that retained appreciable potency
and maximal rat plasma stability (as determined by method 1) were the Arg5 variants
homoarginine (HomoArg5), 4-guanidylphenylalanine (4GuanPhe5) and N-methyl arginine
(NMeArg5). Non-natural substitutions in Ac34-18(TMB)-NH2 that increased potency
compared to the wildtype peptide was the Pro3 analogue azetidine carboxylic acid (Aze3)
and the Ala4 analogue 2-aminobutyric acid (Aba4). Thus, Aze3, Aba4 were combined
with the protease stability enhancing HomoArg5, 4GuanPhe5 and NMeArg5 to ine
whether this would yield peptide candidates with high plasma stability and increased
potency.
Table 15 and 16 present the affinities of the various constructs, together with the plasma
stabilities.
Firstly, quantitative determination of rat plasma halflives (4th column, Table 15) of
ne analogue containing peptides revealed that Arg5 N-methylation was most potent
in protecting the peptide (t1/2 >20 hrs) followed by HomoArg5 and GuanPhe5. The strong
protective effect of Arg N-methylation is perhaps not surprising as it directly prevents
hydrolysis of the e bond. Upon inclusion of Aze3 in these compounds, the affinity of
these peptides could be enhanced in all cases, making Ac-(0618) Aze3 HomoArg5
and Ac-(0618) Aze3 NMeArg5 attractive candidates for further development (Table
, Figure 16).
The ty enhancing effect of Aba4 could not be reproduced in the context of Aze3 and
any of the ne analogues, as Ki values were higher than those observed without
Aba4. Thus, the potency enhancing effects of Aze3 are independent of the type of
ne substitution, while those of Aba4 are likely not.
Finally, the activity s rat Kallikrein of these peptides is reduced significantly (Table
). However, these values are relative and not quantitative at this stage as the n
preparation of rat Kallikrein is not trivial and contained impurities.
Example 6: Plasma stability enhancement of the Trp-free FPYR Kallikrein e
lead and affinity enhancement by Aze3
From the selection output in Examples 1-4 we discovered several sequences resembling
Ac34-18(TMB)-NH2 that had a high abundance, but contained altered WPAR motifs.
These were WPSR and FPYR. The latter in particular is interesting as it lacks the
ion-sensitive tryptophan.
Bicycles containing WPSR, FPYR, WPYR and FPAR were synthesised and compared
against the WPAR parent e (Table 21)
As expected, none of the peptides displayed a significantly different plasma ity. The
replacement of Trp2 with Phe2 incurs a 40-fold reduction in Ki, underlining the
requirement of the bulkier Trp2 side chain. However, this reduction can be compensated
by replacing Ala4 with Tyr4 (giving the FPYR motif), so that the affinity increases again to
almost that of the wildtype WPAR sequence (Ki = 0.46 nM). Thus, there is a cooperative
interplay between the residues at position 2 and position 4 of the Ac34-18(TMB)-NH2
e. Given the high target binding affinity and lack of Trp2 in Ac34-18(TMB)-NH2
Phe2Tyr4, this candidate was investigated for increasing rat plasma half life employing
the approach as described in the example above. r, we investigated the interplay
between Phe2 and Tyr4 by substituting these residues with non-natural amino acid
analogues.
tural tutions of Phe2/Tyr4 in Ac34-18(TMB)-NH2 Phe2Tyr4
We performed a non-exhaustive set of syntheses incorporating replacements on Phe2 or
Tyr4 in the Ac34-18(TMB)-NH2 Phe2Tyr4 lead. Non-natural amino acids were
chosen from the same set as in Figure F6, and affinity data is summarised in Table 22.
Here, substitution with any of the amino acids tested is generally well tolerated,
regardless whether the sidechain is a heteroaromatic (3Pal, 4Pal), aromatic and bulky
(1Nal, 2Nal, 4,4-BPal) or a cycloaliphatic (Cha) entity. 3Pal is well tolerated at position 2
(Ki = 0.91), which is interesting as Pal contains an ionisable group (which could i.e. be
exploited for formulation). It appears, however, that the original Phe2/Tyr4 combination
remains most potent.
Stabilisation of Ac34-18(TMB)-NH2 Phe2Tyr4 in rat plasma and effect of azetidine3
substitution
34-18(TMB)-NH2 Phe2Tyr4 was prepared with the homo-arginine, 4-
guanidylphenylalanine and N-methylarginine substitutions, in absence and presence of
Aze3. HomoArg/4Guanphe are well tolerated, with Ki values almost identical to the parent
Phe2Tyr2 peptide (Table 23,), and rat plasma stability was enhanced by a factor of 13
(t1/2 = 12.2 hrs, Table 23). Moreover, IC50 values for rat rein are similar to that of
parent, indicating this to be an attractive candidate for in vivo s.
Pro3 to Aze3 substitution in the FPYR context again yielded peptide ates with
enhanced affinity, indeed a peptide with a Ki less than 1 nM was generated that would
likely have a greater half-life than 20 hrs in rat (Ac-(0618) Phe2 Aze3Tyr4 NMeArg5).
Unless otherwise stated, any methods and materials similar or equivalent to those
described herein can be used in the ce or testing of the present invention. Methods,
devices, and materials suitable for such uses are described above. All publications cited
herein are incorporated herein by reference in their entirety for the purpose of describing
and disclosing the ologies, ts, and tools ed in the publications that
might be used in connection with the invention.
The term ‘comprising’ as used in this specification and claims means ‘consisting at least
in part of’. When interpreting statements in this specification and claims which includes
the ‘comprising’, other es besides the features prefaced by this term in each
statement can also be present. Related terms such as ‘comprise’ and ‘comprised’ are to
be interpreted in similar manner.
In this specification where reference has been made to patent specifications, other
external documents, or other s of information, this is generally for the purpose of
providing a context for discussing the es of the invention. Unless specifically stated
otherwise, reference to such external documents is not to be construed as an admission
that such documents, or such sources of information, in any jurisdiction, are prior art, or
form part of the common general knowledge in the art.
Tables
Bicyclic Number Ki (nM)
peptide of amino
Orthologous proteases Paralogous proteases
acids in
loops Human Monkey Rat Human Human Human Human
plasma plasma plasma factor Xia thrombin plasmin factor XIIa
kalikrein Kallikrein Kallikrein (hfXIa)
(hPK) (mPK) (rPK)
PK15 6x6 3 4 941 75'000 > 75'000 > 75'000 > 75'000
2A2 5x5 5 6 7 > 75'000 > 75'000 > 75'000 > 75'000
2A10 5x5 18 23 66 75'000 > 75'000 30'000 > 75'000
3B3 3x3 8 11 24 57 > 75'000 > 75'000 > 75'000
3B8 3x3 7 9 12 52 > 75'000 > 75'000 > 75'000
P16 3x3 40 37 53 699 > 75'000 > 75'000 > 75'000
Table 1 Target specificity of bicyclic peptides with different loop lengths. Indicated are Ki
values for hPK and different paralogous and orthologous proteases. Ki values are means
of at least two measurements.
ed region Number Sequence identity with human plasma Kallikrein (hPK)
of amino
Orthologous proteases gous proteases
acids
Monkey Rat Human Human Human Human
plasma plasma factor XIa thrombin plasmin factor XIIa
Kallikrein Kallikrein (hfXIa)
(mPK) (rPK)
All amino acids 95% 81% 69% 36% 34% 35%
Surface amino 4 Å 14 100% 100% 100% 71% 86% 79%
acids within a
8 Å 19 100% 100% 83% 79% 74% 63%
specific distance
of the active site* 12 Å 41 100% 93% 84% 61% 54% 56%
Table 2 Sequence homologies around the active site of paralogous and orthologous
serine proteases of hPK. (*) Based on the crystal structure of hPK (PDB entry 2ANW)
n the bound benzamidine ligand in the S1 pocket was chosen as center.
Table 3: 3x3 peptides
Kallikrei
Peptid Thrombi
Sequence n Av Ki
e n Ic50
(nM)
ACFKHCRVAC
3B8 0.95
A A C F K H C R V A C A >10000
RVAC
3A3 43.1
A A C F P K C R V A C A
3B9 ACFDPCRVICA A C F D P C R V I C A 90.8
ACFKNCRVNC
3B2 A A C F K N C R V N C A
ACFNKCRVNC
06-64 A A C F N K C R V N C A 4.8
RVNC
06-94 A A C F K Q C R V N C A 0.7 >10000
ACFYKCRVNC
06-71 A A C F Y K C R V N C A 15.2
ACFKACRVNC
3B3 0.59
A A C F K A C R V N C A >10000
Table 4: 5x5 peptides
Kalli
krein Thro Fac
Sequence Av mbin tor
Ki Ic50 XIIa
(nM)
ACAWPARC
- A C A W P A R C L T V D L C A <0.1* >100 >10
LTVDLCA
01 00 000
- ACRWPARC <0.3* >100 >10
34 VHQDLCA A C R W P A R C V H Q D L C A 00 000
- ACSWPARC 0.4 >100 >10
57 NHQDLCA A C S W P A R C N H Q D L C A 00 000
- ACRWPARC 0.5 >100 >10
59 LTTSLCA A C R W P A R C L T T S L C A 00 000
0.49
A2 ACRWPARC >100 >10
) T THQNYCA A C R W P A R C T H Q N Y C A 00 000
06 ACTWPARC >100 >10
- THQNWCA A C T W P A R C T H Q N W C A 00 000
- ACFPSHDC
A C F P S H D C D G R R M C A 1.27
14 A >100 >10
3 00 000
- ACGGPQNC 2.1 >100 >10
56 RTWTTCA A C G G P Q N C R T W T T C A 00 000
ACNWPYRC >100 >10
7 LHTDLCA A C N W P Y R C L H T D L C A 00 000
- ACSWPYRC 5.8 >100 >10
61 LHQDYCA A C S W P Y R C L H Q D Y C A 00 000
64 ACGVPYRC >100 >10
T THQEMCA A C G V P Y R C T H Q E M C A 00 000
A2 ACTWPARC >10
* TMQNWCA A C T W P A R C T M Q N W C A 000
1277
63 ACADPWAC >100 >10
T LFRRPCA A C A D P W A C L F R R P C A 00 000
1E ACAWPARC >100 >10
6 LTTSLCG A C A W P A R C L T T S L C G 0.16 00 000
2A ACTYPYKCL
HQNLCA A C T Y P Y K C L H Q N L C A 4.98
1B ACAWPAKC
1 LTRELCA A C A W P A K C L T R E L C A 8.1
1F ACGGYNNC
7 RAFSYCA A C G G Y N N C R A F S Y C A 2.2
Table 5 - 06-34 – substitutions based on identification of non-critical residues with
natural amino acids
Peptide Sequence IC50 human PK IC50 rat PK
(nM) (nM)
06-34 ACRWPARCVHQDLCA* 0.19 7.38
01 ACSWPARCVHQDLCA 0.15 6.12
0602 ACRWPARCTHQDLCA 0.16 1.09
0603 (01+02) ACSWPARCTHQDLCA 0.082 0.87
0604 ACRWPARCMHQDLCA 0.075 0.56
0605 RCLHQDLCA 0.076 0.62
0617 (01+04) ACSWPARCMHQDLCA 0.073 0.44
0618 (01+05) ACSWPARCLHQDLCA 0.070 0.56
0619 KCLHQDLCA 0.19 4.67
(01+05+R/K)
*: Residue numbering is from left to right, where residues 1-5 are in loop 1, and residues
6-10 are in loop 2.
Table 6- 06-34 – substitutions based on identification of non critical residues with N-
ated amino acids
Ki human PK
Peptide Sequence (nM)
06-34 ACRWPARCVHQDLCA 0.128
0603 – Ala1,6 ACAWPARCAHQDLCA 0.147
0603 - N-MeGly1,6 AC N-MeGWPARCN-MeG HQDLCA 24.8
0618 ACSWPARCLHQDLCA 0.040
0618 –N-MeSer1 ACN-MeSWPARCLHQDLCA 0.560
Table 7
Short
Supplier name Full chemical name
AGTC D-Asp Fmoc-D-Asp(tBu)-OH
c NDM-Arg Fmoc-Nwωdimethyl-L-arginine
c r Fmoc - Nα - methyl - O - t - butyl - L - serine
Anaspec NMe-Trp Fmoc - Nα - methyl - L - tryptophan
Anaspec NorHar Fmoc-L-1;2;3;4-tetrahydro-norharmancarboxylic acid
Anaspec lPro Fmoc-(2S;4S)phenyl-pyrrolidinecarboxylic acid
Iris Biotech Agb Fmoc-L-Agb(Boc)2-OH
Iris Biotech Agp Fmoc-L-Agp(Boc)2-OH
Iris h β-Ala Fmoc-beta-Ala-OH
Iris Biotech Cit Fmoc-Cit-OH
Iris Biotech D-Cys Fmoc-D-Cys-OH
Iris Biotech β-HArg Fmoc-L-beta-HArg(Pbf)-OH
Iris Biotech NMe-Arg Fmoc-L-MeArg(Mtr)-OH
Iris Biotech 3Pal Fmoc-L-3Pal-OH
Iris Biotech 4Pal Fmoc-L-4Pal-OH
Iris h Pen Fmoc-Pen(Trt)-OH
Iris Biotech D-Pro Fmoc-D-Pro-OH
Iris Biotech Tic Fmoc-L-Tic-OH
Iris Biotech D-Trp Fmoc-D-Trp-OH
Merck Novabiochem Aib Fmoc-Aib-OH
Merck Novabiochem D-Ala Fmoc-D-Ala-OH
Merck Novabiochem D-Arg Fmoc-D-Arg(Pbf)-OH
Merck Novabiochem 4GuanPhe Fmoc-Phe(bis-Bocguanidino)-OH
Merck Novabiochem D-Gln Fmoc-D-Gln(Trt)-OH
Merck Novabiochem D-His Fmoc-D-His(Trt)-OH
Merck Novabiochem Hyp yp(tBu)-OH
Merck Novabiochem D-Leu Fmoc-D-Leu-OH
Merck Novabiochem a Fmoc-L-MeAla-OH
Merck Novabiochem NMe-Cys Fmoc-N-Me-Cys(Trt)-OH
Merck Novabiochem SDMA Fmoc-SDMA(Boc)2-ONa
Merck Novabiochem HArg Fmoc-L-HArg(Boc)2-OH
h Corporation 4,4-BPAl Fmoc-L-4, 4'-Biphenylalanine
Peptech Corporation 3,3-DPA Fmoc-L-3,3-Diphenylalanine
Peptech Corporation Dpg Fmoc-Dipropylglycine
Peptech Corporation 1NAl Fmoc-LNaphthylalanine
Peptech Corporation 2NAl Fmoc-LNaphthylalanine
Peptech Corporation Pip Fmoc-L-Pipecolic acid
Polypeptide Group Aba Fmoc-Laminobutyric acid
Polypeptide Group Aze Fmoc-L-azetidinecarboxylic acid
Polypeptide Group 4BenzylPro )-Fmocbenzyl-pyrrolidinecarboxylic acid
Polypeptide Group Cha Fmoc-beta-cyclohexyl-L-alanine
Polypeptide Group 4FluoPro (2S,4R)-Fmocfluoro-pyrrolidinecarboxylic acid
Polypeptide Group Ind Fmoc-L-Indolinecarboxylic acid
Table 8
Ki (nM) Observable in
Peptide Sequence (human rat plasma, for
kallikrein) days
Ac-(0618) wildtype Ac-CSWPARCLHQDLC 0.17 2
Ac-(0618) A2A3 Ac-CSAAARCLHQDLC 18545 1
Ac-(0618) A2Q3 Ac-CSAQARCLHQDLC 15840 1
Ac-(0618) Scram1 Ac-CPSAWRCLHQDLC 1091 2
Ac-(0618) Scram2 SPRCLHQDLC 11355 2
Ac-(0618) Scram3 Ac-CAPWSRCLHQDLC 1892 1
Ac-(0618) Scram4 Ac-CWARSPCLHQDLC 67500 1
Table 9
Comparative effects of o acid substitution on potency and rat plasma stability.
Ki (nM) (human Observable
Peptide in rat plasma,
kallikrein) for days
Ac-(0618) wildtype 0.17 2
18) D-Trp2 7558 2
Ac-(0618) D-Pro3 680 3
Ac-(0618) D-Ala4 1203 >10
Ac-(0618) D-Arg5 52 >10
Ac-(0618) D-Cys2 234 >10
Table 10
Comparative s of N-methylation of loop 1 residues and Cys2 on potency and rat
plasma stability.
Ki (nM) (human Observable
Peptide in rat plasma,
kallikrein) for days
Ac-(0618) wildtype 0.17 2
Ac-(0618) NMeSer1 0.5 3
Ac-(0618) NMeSer1, NMeAla4 444 >10
Ac-(0618) NMeTrp2 228 5
Ac-(0618) NMeAla4 343 >10
Ac-(0618) NMeArg5 3.5 >10
Ac-(0618) NMeCys2 418 10
Table 11
Comparative effects of arginine analogues in Ac34-18(TMB)-NH2 on potency and
stability. Note that the D Arg cation did not y any inhibition up to 100 mM
peptide.
Ki (nM) (human Observable
Peptide in rat plasma,
kallikrein) for days
Ac-(0618) wildtype 0.17 2
Ac-(0618) HomoArg5 2.1 >10
Ac-(0618) Agb5 83 >10
18) Agp5 1770 >10
Ac-(0618) bhomoArg5 8.2 >10
Ac-(0618) 4GuanPhe5 0.3 >10
Ac-(0618) SDMA5 1415 >10
Ac-(0618) NDMA5 510 >10
Ac-(0618) Cit5 7860 >10
Ac-(0618) Δ Arg5 >100000 >10
Table 12
ative affinity effects of hydrophobic amino acids substituting Trp2 in Ac34-
18(TMB)-NH2
able
Peptide Ki (nM) (human in rat plasma,
kallikrein) for days
Ac-(0618) wildtype 0.17 2
Ac-(0618) 1NAL2 10.7 2
Ac-(0618) 2NAL2 0.50 2
18) 3Pal2 59 2
Ac-(0618) 4Pal2 72 2
Ac-(0618) Cha2 4.7 2
Ac-(0618) 4,4,BPal2 464 2
Ac-(0618) 3,3-DPA2 1.5 2
Ac-(0618) NorHar2 24 2
Table 13
Comparative affinities obtained for proline derivatives with gamma-carbon substituents,
analogues of varying ring sizes, bi/tricyclic derivatives, and constrained amino acids such
as Aib
Observable
Peptide Ki (nM) (human in rat ,
kallikrein) for days
Ac-(0618) wildtype 0.17 2
Ac-(0618) HyP3 0.41 2
Ac-(0618) 4FluoPro3 0.24 2
Ac-(0618) 4Phenyl Pro3 0.58 2
Ac-(0618) 4Benzyl Pro3 191 2
Ac-(0618) Aze3 0.06 2
Ac-(0618) Pip3 0.26 2
Ac-(0618) Tic3 13.51 2
Ac-(0618) NorHar3 2.99 2
Ac-(0618) Ind3 1.35 2
Ac-(0618) Aib3 1.20 2
Table 14
Comparative effects of miscellaneous substitutions of Ser1, Ala4, and Cys2
Observable
Peptide Ki (nM) (human in rat plasma,
kallikrein) for days
Ac-(0618) wildtype 0.17 2
Ac-(0618) Dpg1 1.09 2
Ac-(0618) Aba4 0.07 2
Ac-(0618) β-Ala4 17450 10
Ac-(0618) Aib4 289 7
Ac-(0618) Cys2ToPen2 2162 5
Table 15
Comparative enhancement in potency d by oration of Aze3 in plasmastabilised
candidates. 1 ative stabilities estimated according to method 1. 2 The
true halflife of peptide stabilities in rat plasma was determined according to method 3. 3
IC50 values are relative, not absolute.
Ki (nM) Observable in t1/2 (hrs)
Peptide IC50 (nM)
(human rat plasma, in rat
rein) for days1 (rat kallikrein) 3
plasma2
Ac-(0618) wildtype 0.17 2.0 2.3 1.7
Ac-(0618) HomoArg5 2.1 >10 10.7 64
Ac-(0618) 4GuanPhe5 0.34 >10 2.8 21
Ac-(0618) NMeArg5 3.5 >10 >20 98
Ac-(0618) Aze3 HomoArg5 0.14 >10 nd nd
18) Aze3 4GuanPhe5 0.17 >10 nd nd
Ac-(0618) Aze3 NMeArg5 1.30 >10 nd nd
Table 16
Effect on potency upon inclusion of Aba4 in peptides ning Aze3 and the plasmastabilising
modifications NMeArg5, HomoArg5, and 4GuanPhe5.
Peptide Ki (nM) (human
kallikrein)
Ac-(0618) wildtype 0.17
Ac-(0618) Aze3 Aba4 NMeArg5 2.8
Ac-(0618) Aze3 Aba4 HomoArg5 0.9
Ac-(0618) Aze3 Aba4 4GuanPhe5 0.2
Table 17
42 unique Kallikrein binders were identified from selections using a randomised WPAR
motif at positions 2, 3, 4 & 5 within the 0603 sequence. The sequences were ranked
according to Kallikrein binding and the ve abundance in the total selection outputs
was noted.
Sequence Rank Frequency
C S W P A R C T H Q D L C 1 24
C S W P S R C T H Q D L C 2 51
C S F P F R C T H Q D L C 3 17
C S W L A R C T H Q D L C 4 8
C S F P Y R C T H Q D L C 5 12
C S F P F K C T H Q D L C 6 4
C S W A A R C T H Q D L C 7 1
C S H P Y R C T H Q D L C 8 2
C S H P F R C T H Q D L C 9 1
C S W P Y R C T H Q D L C 10 3
C R F P F K C T H Q D L C 11 1
C S F P F R C T H Q D L C 12 2
C S L P F R C T H Q D L C 13 3
C S W P F R C T H Q D L C 14 7
C S F P I R C T H Q D L C 15 1
C S L P F K C T H Q D L C 16 1
C S L P F R C T H Q D L C 17 4
C S Y P I R C T H Q D L C 18 2
C S W S A R C T H Q D L C 19 10
C S L P F K C T H Q D L C 20 1
C S Y P F R C T H Q D L C 21 1
C S F P Y K C T H Q D L C 22 1
C S F P W R C T H Q D L C 23 1
C S W H A R C T H Q D L C 24 1
C S L P F R C T H Q D L C 25 2
C S Y P Y R C T H Q D L C 26 2
C S W W A R C T H Q D L C 27 1
C S W P Y K C T H Q D L C 28 1
C S F L Y K C T H Q D L C 29 2
C S L P I R C T H Q D L C 30 1
C S M P Y R C T H Q D L C 31 2
C S I P F K C T H Q D L C 32 1
C S Y P W R C T H Q D L C 33 1
C S F P F W C T H Q D L C 34 1
C S F S Y K C T H Q D L C 35 1
C S W S Y R C T H Q D L C 36 1
C S F M Y K C T H Q D L C 37 1
C S Q V V G C T H Q D L C 38 1
C R W P Y H C T H Q D L C 39 1
C S L F D H C T H Q D L C 40 1
C S H R R W C T H Q D L C 41 1
C S W Q A R C T H Q D L C 42 1
Table 18
A. nce of particular motif in each output. Output sequences were analysed
according to the stringency of selection. The % of a particular motif in the output from a
particular stringency selection was calculated. Also see figure 17.
A Relative abundance of species from different selection encies
WPSR WPAR WSAR WPFR WPYR FPYR FPFR
High 34 17 3 7 3 7 7
Stringency 31 19 3 3 3 3 19
41 13 3 0 0 3 9
26 22 7 0 4 7 4
23 6 6 6 0 16 13
Low 11 4 11 4 0 4 11
B Target binding assay signal
WPSR WPAR WSAR WPFR WPYR FPYR FPFR
178 264 57 67 80 127 171
Binding assay signal 300
Table 19
Top 50 Kallikrein binders ning a WPAR motif. The WPAR domain was fixed in a
e library with positions 1, 6, 7, 8, 9 & 10 randomised. Kallikrein selection output
sequences were isolated and assayed for Kallikrein binding. The sequences were ranked
according to Kallikrein binding. The sequence of e 0603 was isolated from
selection and is highlighted in red. Trends are visible in the second loop of WPAR-
containing Kallikrein-binding peptides.
Rank Sequence Binding assay signal
1 C N W P A R C T H Q D L C 116
2 C S W P A R C T H Q D L C 110
3 C H W P A R C T H Q D L C 110
4 C P W P A R C T H Q D L C 107
C S W P A R C T H A D L C 100
6 C S W P A R C T H D D L C 93
7 C A W P A R C T H T D L C 92
8 C Q W P A R C L H T D L C 91
9 C L W P A R C T H Q D L C 90
C T W P A R C T H T D L C 88
11 C H W P A R C T H Q E L C 85
12 C A W P A R C L H D D L C 84
13 C S W P A R C L H T D L C 83
14 C A W P A R C T H V D L C 82
C A W P A R C T H T D F C 80
16 C M W P A R C M H Q D L C 79
17 C A W P A R C T H A D L C 79
18 C Q W P A R C M H Q D M C 75
19 C Q W P A R C T H S D L C 74
C L W P A R C T H A D L C 74
21 C R W P A R C T H Q D L C 73
22 C Q W P A R C M H Q E L C 73
23 C T W P A R C L H Q D L C 73
24 C S W P A R C T H S H L C 72
C V W P A R C T H Q D L C 71
26 C T W P A R C T H A D L C 71
27 C H W P A R C M H Q D L C 71
28 C P W P A R C T H T D L C 70
29 C A W P A R C T H Y D L C 70
C P W P A R C T H Q N L C 69
31 C S W P A R C T H T E L C 69
32 C A W P A R C M H D D L C 69
33 C S W P A R C L H T E L C 68
34 C S W P A R C I H Q D L C 68
C T W P A R C T H T D M C 67
36 C A W P A R C T H T H L C 66
37 C A W P A R C L H A D M C 66
38 C A W P A R C L H Q D W C 63
39 C D W P A R C M H Q E F C 63
40 C A W P A R C T H Q T M C 61
41 C T W P A R C L H Q H M C 61
42 C S W P A R C V H Q D M C 61
43 C E W P A R C L H T D L C 60
44 C L W P A R C L T T E L C 59
45 C S W P A R C T H A E M C 59
46 C R W P A R C T H T D L C 59
47 C T W P A R C T H Q A F C 59
48 C S W P A R C T H S D L C 59
49 C S W P A R C L H D D L C 59
50 C P W P A R C L H T D L C 58
Table 20
The output sequences from Kallikrein selections with fixed-WPAR in the 1st loop, and their
associated Kallikrein binding assay signals, were grouped according to their derivation
from ‘THxxL’ motif (A), or ‘xHxDL’ motif (B). The e binding assay signal for all
members of a given group was calculated. Groups containing precisely the given motif
are highlighted green; examples of groups with either one more or one less change away
from the motif are also shown.
A B
Groups based on xHxDL motif Groups based on THxxL motif
Motif Bi nding Moti f Bindi ng Motif Binding Motif Binding Motif Bindi ng Moti f Binding
THxDL 78.5 xHxDL 70.9 xHxxL 56.1 THxDL 78.5 THxxL 61.0 MHxxx 56.5
MHxDL 66.7 xHxDM 52.8 xHxxM 46.3 MHxDL 66.7 MHxxL 55.0 THxxx 53.4
LHxDL 58.0 xHxEL 51.7 xHxxF 43.8 LHxDL 58.0 LHxxL 47.9 LHxxx 44.4
THxEL 55.9 xHxHM 46.4 xHxxW 33.2 THxEL 55.9 THxxM 46.3 LTxxx 33.8
THxHL 52.5 xHxNL 46.2 xTxxL 31.1 THxHL 52.5 LHxxM 39.0
LHxEL 52.3 xHxDW 44.2 xHxxE 19.3 LHxEL 52.3 LTxxL 38.4
THxNL 51.9 xHxHL 44.2 THxNL 51.9
THxDW 44.9 xHxFL 40.4 THxFL 40.4
LHxDW 44.7 xTxEL 39.9 LTxEL 39.9
MHxEL 42.4 xTxDL 39.4 LTxDL 39.4
LTxEL 39.9 xHxQL 39.0 LHxSL 37.4
LTxDL 39.4 xHxAL 35.5 THxAL 35.5
LHxQL 39.0 xHxSL 35.0 LHxHL 34.0
LHxDM 38.0 xTxSL 33.1 LTxSL 33.1
LHxSL 37.4 xHxYL 29.2 THxSL 28.9
THxAL 35.5
LHxHL 34.0
LTxSL 33.1
THxSL 28.9
Table 21
Affinities and stabilities of WPAR motif variants.
Observable
Peptide Ki (nM) (human in rat ,
kallikrein) for days
Ac-(0618) WPAR 0.17 2
Ac-(0618) FPAR 6.28 2
18) WPYR 0.41 2
Ac-(0618) WPSR 0.44 2
Ac-(0618) FPYR 0.46 2
Table 22
Effect of substitutions on Phe2/Tyr4 with hydrophobic analogues
Peptide Ki (nM) (human
kallikrein)
Ac-(0618) Phe2 Tyr4 0.46
Ac-(0618) Phe2 Cha4 0.91
Ac-(0618) Phe2 3Pal4 2.57
Ac-(0618) Phe2 4Pal4 2.20
Ac-(0618) Phe2 1Nal4 13.5
Ac-(0618) Phe2 2Nal4 7.27
Ac-(0618) Phe2 4,4-BPal4 10.5
Ac-(0618) 3Pal2 Tyr4 0.91
18) 4Pal2 Tyr4 3.56
Ac-(0618) Cha2 Tyr4 1.87
Table 23
Summary of the effect of Arg5 substitutions and Aze3 on Ac34-18(TMB)-NH2
Phe2Tyr4. 1 Comparative stabilities estimated according to method 1. 2 The true halflife of
e stabilities in rat plasma was determined according to method 3. 3 IC50 values are
relative, not absolute.
IC50
Ki (nM) Observable t1/2 (hrs) in
Peptide (human in rat plasma, rat (nM)
rein) for days1 plasma2 (rat
kallikrein)3
Ac-(0618) Phe2 Tyr4 0.46 2 0.9 13.8
Ac-(0618) Phe2 Tyr4 HomoArg5 0.77 >10 12.2 19.7
Ac-(0618) Phe2 Tyr4 4GuanPhe5 0.40 >10 5.0 2.5
Ac-(0618) Phe2 Tyr4 NMeArg5 3.56 >10 >20 60.2
Ac-(0618) Phe2 Aze3 Tyr4 HomoArg5 0.12 nd nd nd
18) Phe2 Aze3Tyr4 4GuanPhe5 0.36 nd nd nd
Ac-(0618) Phe2 Aze3Tyr4 NMeArg5 0.97 nd nd nd
Claims (29)
1. A peptide ligand specific for human Kallikrein comprising a polypeptide comprising at least three reactive groups, separated by at least two loop sequences, and a molecular scaffold which forms covalent bonds with the reactive groups of the polypeptide such that at least two polypeptide loops are formed on the lar ld, n the loops of the e ligand comprise three, four or five, but less than six, amino acids.
2. A e ligand ing to claim 1, wherein the loops of the peptide ligand comprise three amino acids and the polypeptide has the consensus sequence GrFxxGrRVxGr, wherein Gr is a reactive group.
3 A peptide ligand according to claim 2, which comprises one of the polypeptides set forth in Table 3.
4. A peptide ligand according to claim 1, wherein the loops of the peptide ligand comprise five amino acids and a first loop comprises the consensus sequence GrGGxxNGr, wherein Gr is a reactive group.
5. A peptide ligand according to claim 4, wherein two adjacent loops comprise the consensus sequence GrGGxxNGrRxxxxGr.
6. A peptide ligand according to claim 4 or claim 5, which comprises one of the es set forth in Table 4.
7. A peptide ligand according to claim 1, wherein the loops of the peptide ligand comprise five amino acids and a first loop ses the motif GrxW/FPxK/RGr, wherein Gr is a reactive group.
8. A e ligand according to claim 7, further comprising a second loop which comprises the motif GrT/LHQ/TxLGr.
9. A peptide ligand according to claim 1, wherein the loops of the peptide ligand comprise five amino acids and a first loop comprises the motif GrxHxDLGr, wherein Gr is a reactive group.
10. A peptide ligand according to claim 1, wherein the loops of the peptide ligand comprise five amino acids and a first loop comprises the motif GrTHxxLGr, wherein Gr is a reactive group.
11. A peptide ligand ing to any one of claims 8 to 10, wherein two adjacent loops comprise the motif GrxW/FPxK/RGrT/LHQ/TDLGr.
12. A peptide ligand according to any one of claims 7 to 11, which comprises one of the polypeptides set forth in Table 4, Table 5 or Table 6.
13. A peptide ligand according to any one of claims 7 to 11, wherein the first loop comprises the sequence GrxWPARGr.
14. A peptide ligand according to any one of claims 7 to 11, wherein the first loop ses the sequence GrxWPSRGr.
15. A peptide ligand according to any one of claims 7 to 11, wherein the first loop comprises the sequence GrxFPFRGr.
16. A peptide ligand according to any one of claims 7 to 11, wherein the first loop comprises the sequence GrxFPYRGr.
17. A peptide ligand according to any one of claims 13 to 16, wherein x is S or R.
18. A peptide ligand according to any ing claim, wherein the reactive group is cysteine.
19. A peptide ligand according to any preceding claim which ses one or more non-natural amino acid substituents and is resistant to protease degradation.
20. A peptide ligand according to claim 19, wherein the modified amino acid is selected from N-methyl Arginine, homo-arginine, hydroxyproline, and guanidylphenylalanine , and azetidine carboxylic acid.
21. A e ligand according to claim 20, n the polypeptide comprises a first loop which comprises the motif GrxWPARGr, wherein Pro is replaced with azetidine carboxylic acid; and/or R is replaced with N-methyl arginine or homoarginine or guanidylphenylalanine.
22. A peptide ligand according to claim 20, wherein the ptide ses a first loop which comprises the motif GrxFPYRGr, wherein Pro is replaced with azetidine carboxylic acid; and/or R is replaced with N-methyl neor homoarginine, or guanidylphenylalanine.
23. A peptide ligand according to claim 22, wherein the polypeptide comprises a first loop which comprises the motif RGr, wherein Pro is replaced with azetidine carboxylic acid; and/or R is replaced with homoarginine.
24. A peptide ligand according to claim 23, wherein the polypeptide comprises a first loop which comprises the motif GrxFPYRGr, wherein Pro is replaced with azetidine carboxylic acid and R is replaced with homoarginine.
25. A e ligand according to any one of claims 21 to 24, wherein x is S.
26. A peptide ligand according to any one of the preceding claims, which onally comprises an N-terminal alanine residue.
27. A peptide ligand according to any one of ing claims, which comprises N- terminal acetylation and C-terminal amidation.
28. A peptide ligand according to claim 1 or claim 19, which comprises one of the polypeptides set forth in Table 9, Table 10, Table 11, Table 12, Table 13, Table 15, Table 16, Table 17, Table 19, Table 21, Table 22 or Table 23.
29. A peptide ligand as d in any one of claims 1 to 28, substantially as herein described and with reference thereof.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1117408.3A GB201117408D0 (en) | 2011-10-07 | 2011-10-07 | Modulation of structure polypeptide specificity |
GB1117408.3 | 2011-10-07 | ||
GB1205612.3 | 2012-03-29 | ||
GBGB1205612.3A GB201205612D0 (en) | 2012-03-29 | 2012-03-29 | Modulation of structured polypeptide specificity |
PCT/EP2012/069898 WO2013050616A1 (en) | 2011-10-07 | 2012-10-08 | Modulation of structured polypeptide specificity |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ623518A NZ623518A (en) | 2016-06-24 |
NZ623518B2 true NZ623518B2 (en) | 2016-09-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11912794B2 (en) | Modulation of structured polypeptide specificity | |
US11753444B2 (en) | Modulation of structured polypeptide specificity | |
JP6437468B2 (en) | Polypeptide modification | |
WO2013050617A1 (en) | Structured polypeptides with sarcosine linkers | |
NZ623518B2 (en) | Modulation of structured polypeptide specificity |